Adynxx (ADYX) 10-K 24 Feb 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 17, 2015	Jun. 30, 2014
Document Information [Line Items]
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1054274
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		16,825,095
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$69,113,220

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$16,770,879	$12,100,544
Accounts receivable	968,616	156,831
Inventory, net	1,411,748	501,469
Prepaid expenses and other current assets	477,824	88,390
Total current assets	19,629,067	12,847,234
Improvements and equipment, net	1,434,027	1,745,248
Intangible assets, net	4,387,293	2,258,477
Goodwill	4,100,295	425,969
Other assets	173,042	174,640
Total assets	29,723,724	17,451,568
Current Liabilities:
Accounts payable	1,757,742	746,609
Accrued expenses and other current liabilities	2,067,859	1,340,057
Payable for distribution rights	0	333,333
Warrant liability	304,223	933,465
Total current liabilities	4,129,824	3,353,464
Contingent consideration	2,931,598	0
Deferred tax obligation	67,000	53,000
Other long-term liabilities	84,071	92,408
Total liabilities	7,212,493	3,498,872
Commitments and Contingencies
Stockholders' Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 45,714,286 shares authorized; 16,202,689 and 11,484,191 shares issued and outstanding as of December 31, 2014 and 2013, respectively	16,203	11,484
Additional paid-in capital	92,537,742	58,538,491
Accumulated deficit	-70,042,714	-44,597,279
Total stockholders' equity	22,511,231	13,952,696
Total liabilities and stockholders' equity	$29,723,724	$17,451,568

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	45,714,286	45,714,286
Common stock, shares issued	16,202,689	11,484,191
Common stock, shares outstanding	16,202,689	11,484,191

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue, net of returns, allowances and discounts	$4,786,131	$1,797,745
Cost of revenues	3,270,955	2,047,033
Gross profit (loss)	1,515,176	-249,288
Operating expenses
Selling, general and administrative, (inclusive of stock-based compensation of $10,530,265 and $5,513,861 for the years ended December 31, 2014 and 2013 - see Note 10)	26,155,008	11,719,998
Research and product development	0	63,204
Impairment of in-process research and development	0	8,100,000
Acquisition-related expenses	546,970	0
Change in fair value of contingent consideration liability	231,598	0
Total operating expenses	26,933,576	19,883,202
Loss from operations	-25,418,400	-20,132,490
Other income (expense)
Interest expense	-384	-4,807
Interest income	30,739	2,913
Change in value of warrant liability	-43,390	-1,833,498
Total other expense	-13,035	-1,835,392
Loss before income tax provision	-25,431,435	-21,967,882
Income tax provision	14,000	9,000
Net loss	-25,445,435	-21,976,882
Deemed dividend to preferred stockholders	0	-462,006
Net loss attributable to common stockholders	($25,445,435)	($22,438,888)
Basic and diluted net loss per common share (in dollars per share)	($1.74)	($3.14)
Weighted average shares used in computing basic and diluted net loss per common share (in shares)	14,628,981	7,140,613

CONSOLIDATED_STATEMENTS_OF_OPE1

CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Allocated Share-based Compensation Expense	$10,530,265	$5,513,861

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (USD $)		Total	Redeemable Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2012		$12,150,654	$0	$5,925	$34,785,126	($20,000)	($22,620,397)
Balance (in shares) at Dec. 31, 2012			0	5,924,627
Issuance of common stock for the purchase of Choice Therapeutics, Inc.		0
Issuance of common stock for cash, net of issuance costs		15,777,293	0	4,599	15,772,694	0	0
Issuance of common stock for cash, net of issuance costs (in shares)			0	4,599,334
Issuance of preferred stock for cash, net of cash issuance costs of $70,000, warrant issuance costs of $43,906 and $369,903 discount attributable to warrant and beneficial conversion feature		413,809	516,191	0	413,809	0	0
Issuance of preferred stock for cash, net of cash issuance costs of $70,000, warrant issuance costs of $43,906 and $369,903 discount attributable to warrant and beneficial conversion feature (in shares)			250,000	0
Preferred stock contingent beneficial conversion feature triggered due to price reset provision		89,379	-89,379	0	89,379	0	0
Accretion of discount as deemed dividend on preferred stock		-462,006	462,006	0	-462,006	0	0
Conversion of preferred stock into common stock		888,818	-888,818	280	888,538	0	0
Conversion of preferred stock into common stock (in shares)			-250,000	279,505
Issuance of common stock for services		87,379	0	26	87,353	0	0
Issuance of common stock for services (in shares)			0	26,264
Issuance of common stock to related party for services		1,221,708	0	372	1,221,336	0	0
Issuance of common stock to related party for services (in shares)			0	372,330
Exercise of warrants		0	0	261	-261	0	0
Exercise of warrants (in shares)			0	261,030
Extinguishment of warrant liability		1,505,770	0	0	1,505,770	0	0
Receipt of subscription receivable		20,000	0	0	0	20,000	0
Stock-based compensation		4,204,774	0	21	4,204,753	0	0
Stock-based compensation (in shares)			0	21,101
Fair value of rent provided by related party		32,000	0	0	32,000	0	0
Net loss		-21,976,882	0	0	0	0	-21,976,882
Balance at Dec. 31, 2013		13,952,696	0	11,484	58,538,491	0	-44,597,279
Balance (in shares) at Dec. 31, 2013			0	11,484,191
Issuance of common stock for the purchase of Choice Therapeutics, Inc.		1,992,854	0	274	1,992,580		0
Issuance of common stock for the purchase of Choice Therapeutics, Inc. (in shares)			0	273,368
Issuance of common stock for cash, net of issuance costs		14,372,503	0	2,139	14,370,364		0
Issuance of common stock for cash, net of issuance costs (in shares)			0	2,139,287
Exercise of common stock options, net of tendered shares		1,371,914	0	307	1,371,607		0
Exercise of common stock options, net of tendered shares (in shares)			0	306,403
Preferred stock contingent beneficial conversion feature triggered due to price reset provision		0
Issuance of common stock for services		195,338	0	23	195,315		0
Issuance of common stock for services (in shares)			0	23,396
Exercise of warrants		5,225,587	0	977	5,224,610		0
Exercise of warrants (in shares)			0	977,313
Cashless exercise of warrants		0	0	211	-211		0
Cashless exercise of warrants (in shares)			0	211,295
Extinguishment of warrant liability		672,632	0	0	672,632		0
Stock-based compensation	[1]	10,841,897	0	837	10,841,060		0
Stock-based compensation (in shares)	[1]		0	836,491
Net settlement on vesting of restricted stock awards		-668,755	0	-98	-668,657		0
Net settlement on vesting of restricted stock awards (in shares)			0	-98,023
Warrant exchange		0	0	49	-49		0
Warrant exchange (in shares)			0	48,968
Net loss		-25,445,435	0	0	0		-25,445,435
Balance at Dec. 31, 2014		$22,511,231	$0	$16,203	$92,537,742	$0	($70,042,714)
Balance (in shares) at Dec. 31, 2014			0	16,202,689
[1]	Includes $307,189 that was part of accrued expenses as of December 31, 2013 and for the year then ended, which was credited to equity upon the issuance of 34,086 restricted common shares during the year ended December 31, 2014.

CONSOLIDATED_STATEMENT_OF_STOC1

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY [Parenthetical] (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities		$307,189
Debt Conversion, Converted Instrument, Shares Issued	34,086
Payments of Stock Issuance Costs	602,500	680,132
Stock Issuance Costs		70,000
Warrant Issuance Costs		43,906
Discount Attributable To Warrant		369,903
Shares Withheld For Employee Taxes		14,299
Warrant [Member]
Payments of Stock Issuance Costs	$267,174

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net loss	($25,445,435)	($21,976,882)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,080,334	674,225
Amortization of deferred lease incentive	-8,337	-695
Deferred income taxes	14,000	9,000
Provision for inventory obsolescence	-75,486	58,930
Loss on disposal of property and equipment	0	19,236
Stock-based compensation expense	10,534,708	4,204,774
Impairment of in process research and development	0	8,100,000
Stock issued for services rendered	195,338	87,379
Stock issued for services rendered by related parties	0	1,221,708
Change in value of warrant liability	43,390	1,833,498
Fair value adjustment to contingent consideration	231,598	0
Fair value of rent provided by related party	0	32,000
Changes in operating assets and liabilities:
Accounts receivable	-800,198	-47,965
Inventory	-437,832	-241,073
Prepaid expenses and other current assets	-387,837	105,257
Accounts payable	937,639	173,974
Accrued expenses and other current liabilities	826,659	977,595
Net Cash Used in Operating Activities	-13,291,459	-4,769,039
Cash Flows From Investing Activities
Payment for distribution rights	-333,333	-66,667
Purchase of improvements and equipment	-6,596	-51,400
Acquisition of business, net of $474 cash acquired	-1,999,526	0
Net Cash Used in Investing Activities	-2,339,455	-118,067
Cash Flows From Financing Activities
Net proceeds from issuance of common stock	14,372,503	15,797,293
Net proceeds from issuance of preferred stock	0	930,000
Proceeds from the exercise of stock options	1,371,914	0
Proceeds from the exercise of warrants	5,225,587	0
Payment of withholding taxes related to stock-based employee compensation	-668,755	0
Net Cash Provided by Financing Activities	20,301,249	16,727,293
Net Increase in Cash and Cash Equivalents	4,670,335	11,840,187
Cash and Cash Equivalents - Beginning of year	12,100,544	260,357
Cash and Cash Equivalents - End of year	16,770,879	12,100,544
Supplemental Disclosure of Cash Flows Information
Cash paid during the period for Interest	384	4,807
Non-cash investing and financing activities:
Cashless warrant exercise	672,632	1,505,770
Leasehold improvements provided by landlord	0	101,440
Warrant issued to placement agent in connection with preferred stock	0	43,906
Warrant and beneficial conversion feature issued to investor as discount in connection with preferred stock	0	369,903
Preferred stock contingent beneficial conversion feature triggered due to price reset provision	0	89,379
Deemed dividend on preferred stock	0	462,006
Conversion of preferred stock into common stock	0	888,818
2013 Bonus awarded in equity	307,189	0
Warrant exchange	49	0
Acquisition of business:
Current assets, excluding cash and cash equivalents	408,548	0
Intangibles	2,683,000	0
Goodwill	3,674,326	0
Liabilities assumed	-73,494	0
Contingent consideration	-2,700,000	0
Issuance of common stock for acquisition	($1,992,854)	$0

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS [Parenthetical] (USD $)	Dec. 31, 2014
Acquisition of business, net cash acquired	$474

Description_of_Business_and_Ba

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]		1	Description of Business and Basis of Presentation
	Alliqua BioMedical, Inc. (the “Company”) is a provider of advanced wound care solutions. The Company’s primary business strategy is to create superior outcomes for patients, providers, and partners through its hydrogel technology platform and licensed and proprietary products.  The Company’s core businesses include advanced wound care and contract manufacturing. The Company seeks to leverage its proprietary hydrogel and licensed technology platform to add value to its own products and those of its partners.
	On May 5, 2014, the Company acquired Choice Therapeutics, Inc. (“Choice”), a privately held wound care company.
	On June 5, 2014, the Company’s shareholders approved an agreement and plan of merger between the Company and its wholly-owned Delaware subsidiary, Alliqua BioMedical, Inc., pursuant to which the Company merged with and into Alliqua BioMedical, Inc. for the sole purpose of changing the Company’s name to Alliqua BioMedical, Inc. and state of domicile from Florida to Delaware.
	Principles of Consolidation
	The accompanying consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries, AquaMed Technologies, Inc., HepaLife Biosystems, Inc., Alliqua BioMedical SUB, Inc. and Choice Therapeutics, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
	Reclassifications
	Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
	Reverse Stock Split
	The Company effected a 1-for-43.75 reverse stock split of its outstanding common stock on November 18, 2013. The accompanying consolidated financial statements and accompanying notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. The shares of common stock retained a par value of $0.001 per share. Accordingly, stockholders’ equity reflects the reverse stock split by reclassifying from common stock to additional paid-in capital an amount equal to the par value of the decreased shares resulting from the reverse stock split.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies
	Use of Estimates in the Financial Statements
	The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles and goodwill. Actual results could differ from the estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company’s balance of cash and cash equivalents at December 31, 2014 and 2013 consisted principally of bank deposits. From time to time, the Company’s cash account balances may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation guarantee limit. The Company reduces its exposure to credit risk by maintaining its cash deposits with major financial institutions and monitoring their credit ratings.
	Accounts Receivable
	Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. The Company’s accounts receivable balance is a result of product sales and contract manufacturing. These receivables have historically been paid timely.  Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of collection.  If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required.
	Inventory
	Inventory is valued at the lower of cost or market on a first-in, first-out basis. Reserves for inventory obsolescence are based on expiration date and are utilized to account for slow-moving inventory. At December 31, 2014 and 2013, the Company had reserves for obsolete inventory of $1,094 and $76,580, respectively.
	Improvements and Equipment
	Improvements and equipment are recorded at cost. Depreciation of equipment is computed utilizing the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed utilizing the straight-line method over the shorter of the remaining lease term or estimated useful life. Repairs and maintenance costs are expensed as incurred. Additions and betterments are capitalized.
	Acquired In-Process Research and Development
	In-process research and development (“IPR&D”) represents the fair value assigned to incomplete research projects that the Company acquires through business combinations which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. During the year ended December 31, 2013, we recognized impairment of our HepaMate™ patented biotech technologies IPR&D of $8,100,000 as we believed there were impairment triggering events and circumstances which warranted an evaluation of certain indefinite-lived intangible assets.
	Goodwill and Other Intangible Assets
	The Company accounts for goodwill and intangible assets in accordance with the accounting guidance which requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. The Accounting Standards Codification (“Codification”) requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment). Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgment is required to estimate the fair value of reporting units which includes estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment.
	When testing goodwill for impairment, the Company may assess qualitative factors for some or all of its reporting units to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment for some or all of our reporting units and perform a detailed quantitative test of impairment (step 1). If the Company performs the detailed quantitative impairment test and the carrying amount of the reporting unit exceeds its fair value, the Company would perform an analysis (step 2) to measure such impairment. In 2014, the Company first performed a qualitative assessment to identify and evaluate events and circumstances to conclude whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount. Based on the Company’s qualitative assessments, the Company concluded that a positive assertion can be made from the qualitative assessment that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount. In accordance with the Codification, the Company reviews the carrying value of its intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group, if any, exceeds its fair market value. No impairment was deemed to exist as of December 31, 2014.
	Impairment of Long-Lived Assets Subject to Amortization
	The Company amortizes intangible assets with finite lives over their estimated useful lives and reviews them for impairment annually or whenever impairment exists. The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. As of December 31, 2014, Company management believed that no revision to the remaining useful lives or write-down of the Company’s long-lived assets was required, and similarly, no such revisions were required for the year ended December 31, 2014.
	Fair Value of Financial Instruments
	The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments.
	Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:
	Level 1: Observable prices in active markets for identical assets and liabilities.
	Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities.
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title and risk of loss have passed to the customer, there is a fixed or determinable sales price, and collectability of that sales price is reasonably assured. Deposits received on product orders are recorded as deferred revenue until revenues are generally earned when the products are shipped to customers.
	Cost of Goods Sold and Selling, General and Administrative Expenses
	Costs associated with the production and procurement of product are included in cost of goods sold, including shipping and handling costs such as inbound freight costs, purchasing and receiving costs, inspection costs and other product procurement related charges. All other expenses, excluding interest and income taxes, are included in selling, general and administrative expenses, as the predominant expenses associated therewith are general and administrative in nature.
	Advertising Expenses
	Advertising and marketing costs are expensed as incurred. Advertising expenses for the years ended December 31, 2014 and 2013 were $1,607,016 and $298,860, respectively.
	Shipping and Handling
	Certain shipping and handling costs are paid for by the Company. Shipping and handling costs amounted to approximately $52,884 and $23,523 as of December 31, 2014 and 2013, respectively, and are included in cost of revenues.
	Income Taxes
	The Company accounts for income taxes pursuant to the asset and liability method which requires us to recognize current tax liabilities or receivables for the amount of taxes we estimate are payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts and their respective tax bases of assets and liabilities and the expected benefits of net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible.
	The Company adopted the provisions of Accounting Standards Codification Topic 740 (“ASC 740”) related to the accounting for uncertainty in income taxes recognized in an enterprise's consolidated financial statements. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns.
	The benefit of tax positions taken or expected to be taken in the Company's income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryover or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. Interest costs and related penalties related to unrecognized tax benefits are required to be calculated, if applicable. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses. No interest or penalties were recorded during the years ended December 31, 2014 and 2013. As of December 31, 2014 and December 31, 2013, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.
	Common Stock Purchase Warrants
	The Company assesses classification of common stock purchase warrants at each reporting date to determine whether a change in classification between assets and liabilities or equity is required.  The Company’s free standing derivatives consist of warrants to purchase common stock that were issued pursuant to a securities purchase agreement on November 8, 2012.  The Company evaluated the common stock purchase warrants to assess their proper classification in the consolidated balance sheet and determined that the common stock purchase warrants contain exercise reset provisions.  Accordingly, these instruments have been classified as warrant liabilities in the accompanying consolidated balance sheets as of December 31, 2014 and 2013.  The Company re-measures warrant liabilities at each reporting and exercise date, with changes in fair value recognized in earnings for each reporting period.
	Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period services are required to be provided in exchange for the award, usually the vesting period. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award. Stock-based compensation expense is reflected within cost of revenues and operating expenses in the consolidated statements of operations. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.
	Net Loss Per Common Share
	Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during the periods presented. Common stock equivalents, consisting of warrants, stock options, non-vested restricted stock units (“RSUs”), and non-vested shares of restricted stock, were not included in the calculation of the diluted loss per share because their inclusion would have been anti-dilutive.
	The total common shares issuable upon the exercise of stock options, warrants, non-vested RSUs and non-vested restricted stock are as follows:
		As of December 31,
		2014	2013
	Stock options	4,817,660	4,985,586
	Warrants	2,675,121	3,822,557
	Non-vested restricted stock units	-	35,376
	Non-vested restricted stock	188,149	-
	Total	7,680,930	8,843,519

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3	Acquisitions
	On May 5, 2014, the Company acquired all outstanding equity interest of Choice Therapeutics, Inc., a provider of innovative wound care products using proprietary Therabond 3D® Antimicrobial Barrier Systems. The Company’s initial cash payment for this acquisition was $2.0 million and approximately $2.0 million in common stock. In addition to the initial cash payment, the Company may pay up to $5.0 million in contingent consideration which may be earned based upon the acquired company achieving specific performance metrics over the next three twelve month periods, ended April 30, 2017. See Note 14 – Fair Value Measurement for details related to fair value of the contingent consideration.
	The assets and liabilities of the acquired business were included in the Company’s consolidated balance sheet based upon estimated fair values on the date of acquisition as determined in the purchase price allocation, using available information and making assumptions management believes are reasonable. The consolidated statements of operations include the results of the Choice operations beginning May 6, 2014. The Company’s allocation of purchase price for this acquisition is included in the table below, which summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition:
	Consideration:
	Common stock		$	1,992,854
	Cash paid			2,000,000
	Fair value of contingent consideration			2,700,000
	Total consideration			6,692,854
	Cash			474
	Inventory			396,961
	Other assets			11,587
	Tradenames			111,000
	Technology			2,396,000
	Customer relationships			176,000
	Goodwill			3,674,326
	Other liabilities			-73,494
	Net assets acquired		$	6,692,854
	The amortization period of intangible assets acquired ranges from 3 to 12 years. The Company recorded approximately $3.7 million of goodwill in connection with this acquisition, reflecting the strategic fit and revenue and earnings growth potential of this business.
	Revenues included in the consolidated statement of operations for the year ended December 31, 2014 from this acquisition for the period subsequent to the closing of the transaction was approximately $1.5 million. Loss from operations included in the consolidated statement of operations for the year ended December 31, 2014 from this acquisition for the period subsequent to the closing of the transaction was approximately $136,000. Also included in the loss from operations in the year ended December 31, 2014 is approximately $232,000 relating to adjustments to the fair value of contingent consideration described below, and approximately $200,000 of amortization relating to intangibles.
	The following unaudited pro forma results of operations for the year ended December 31, 2014 and 2013 assumes that the above acquisition was made at the beginning of the year prior to the acquisition. The pro forma results were calculated applying the Company’s accounting policies and reflect the elimination of transaction costs related to the acquisition that were included in the Company’s results of operations for the year ended December 31, 2014. The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisitions had actually occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future.
			Pro forma Results for the
			Year Ended December 31,
			2014		2013
	Revenues		$	5,475,959	$	3,593,933
	Net loss		$	-25,522,302	$	-22,713,859
	During the year ended December 31, 2014, the Company incurred acquisition-related costs of approximately $547,000 in connection with due diligence, professional fees, and other expenses. Additionally, the Company adjusts the fair value of certain acquisition-related contingent consideration liabilities on a quarterly basis. For the year ended December 31, 2014, the adjustments resulted in a net increase of approximately $232,000 to the Company’s acquisition-related contingent consideration liability and corresponding increase in operating expenses.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	4	Inventory
	Inventory consists of the following:
			December 31,
			2014		2013
	Raw materials		$	197,514	$	174,176
	Work in process			489,431		57,030
	Finished goods			725,897		346,843
	Less: Inventory reserve			-1,094		-76,580
	Total		$	1,411,748	$	501,469

Improvements_and_Equipment_net

Improvements and Equipment, net	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5	Improvements and Equipment, net
	Improvements and equipment consist of the following:
				December 31,
			Useful Life	2014		2013
			(Years)
	Machinery and equipment		10	$	2,869,453	$	2,869,453
	Office furniture and equipment		10-Mar		51,439		44,844
	Leasehold improvements		(A)		228,021		228,021
					3,148,913		3,142,318
	Less: Accumulated depreciation and amortization				-1,714,886		-1,397,070
	Improvements and equipment, net			$	1,434,027	$	1,745,248
	(A) Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.
	Depreciation and amortization expense was $317,817 and $303,535 for the years ended December 31, 2014 and 2013, respectively.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	6	Intangible Assets
	The gross carrying amount and accumulated amortization of intangible assets as of December 31, 2014 and 2013 are as follows:
					December 31, 2014
			Useful Life		Gross		Accumulated				Net
											Carrying
			(Years)		Amount		Amortization		Impairment		Amount
	Technology		10		$	5,396,000	$	-1,934,733	$	-	$	3,461,267
	Customer relationships		12-Sep			776,000		-308,871		-		467,129
	Distribution rights		5.27			400,000		-96,880		-		303,120
	Tradename		3			111,000		-24,667		-		86,333
	Non-compete		1			208,333		-138,889		-		69,444
					$	6,891,333	$	-2,504,040	$	-	$	4,387,293
					December 31, 2013
			Useful Life		Gross		Accumulated				Net
											Carrying
			(Years)		Amount		Amortization		Impairment		Amount
	In process research and development				$	8,100,000	$	-	$	-8,100,000	$	-
	Technology		10			3,000,000		-1,475,000		-		1,525,000
	Customer relationships		12			600,000		-245,834		-		354,166
	Distribution rights		5.27			400,000		-20,689		-		379,311
					$	12,100,000	$	-1,741,523	$	-8,100,000	$	2,258,477
	Amortization expense attributable to intangible assets for the years ended December 31, 2014 and 2013 was $762,517 and $370,690, respectively. During the year ended December 31, 2013, the Company recognized an impairment charge of $8,100,000 related to its in process research and development.
	Amortization expense in each of the five years and thereafter subsequent to December 31, 2014 related to the Company’s intangible assets is expected to be as follows:
			Expected
			Amortization
			Expense
	2015			791,790
	2016			722,346
	2017			697,679
	2018			683,704
	2019			334,156
	Thereafter			1,157,618
	Total		$	4,387,293

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7	Accrued Expenses
	Accrued expenses consist of the following:
			December 31,
			2014		2013
	Salaries, benefits and incentive compensation		$	1,528,229	$	1,036,771
	Professional fees			228,426		83,317
	Royalty fees			100,537		-
	Inventory			-		127,786
	Deferred revenue			78,523		39,000
	Deferred lease incentive liability			8,337		8,337
	Other			123,807		44,846
	Total accrued expenses and other current liabilities		$	2,067,859	$	1,340,057

Operating_Leases

Operating Leases	12 Months Ended
	Dec. 31, 2014
Leases, Operating [Abstract]
Leases of Lessee Disclosure [Text Block]	8	Operating Leases
	The Company has an obligation for its corporate offices and commercial manufacturing facility located at 2150 Cabot Boulevard West, Langhorne, Pennsylvania. In 2013, the Company extended its lease for it operating facilities in Langhorne, PA for an additional period of 10 years commencing on February 1, 2016 and continuing through and including January 31, 2026. Under the extended lease, the landlord agreed to make certain improvements to the facility. For tenant improvements funded by the landlord, the Company recorded a deferred lease incentive liability in accrued and other long-term liabilities on the consolidated balance sheet and amortizes the deferred liability as a reduction to rent expense on the consolidated statement of operations over the term of the lease. Tenant improvements are also included in leasehold improvements on the balance sheet. At December 31, 2014, the deferred lease incentive liability was $92,408.
	Total rent expense was $206,690 and $204,930 for the years ended December 31, 2014 and 2013, respectively.
	Future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases in each of the five years and thereafter subsequent to December 31, 2014 are as follows:
	2015		$	206,250
	2016			207,309
	2017			207,405
	2018			207,405
	2019			207,405
	Thereafter			1,261,714
	Total		$	2,297,488

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	9	Commitments and Contingencies
	Employment Agreements for Former Employees
	On March 14, 2014, a former executive of the Company resigned. Upon the executive’s resignation, the Company entered into a general release and severance agreement with this executive, pursuant to which, the employment agreement between the executive and the Company, dated September 28, 2012, was terminated, except for provisions relating to confidentiality and restrictive covenants. The Company provided the executive with: (i) payments totaling $385,000; (ii) the full and immediate vesting of all outstanding stock options and RSUs granted to this executive, with such stock options remaining exercisable for a period of two years following the date of resignation; and (iii) continued health insurance coverage during the six-month severance period. Of the total payments due to this executive, $210,000 was related to 2013 performance and was included in accrued expenses as of December 31, 2013. The expense of the accelerated vesting of outstanding stock options and RSUs was $873,411 and is included in stock-based compensation for the year ended December 31, 2014. All commitments under this severance agreement have been satisfied.
	In March 2014, the Company entered into general release and severance agreements with two employees, pursuant to which each employee’s employment with the Company was terminated effective immediately. The Company provided the employees with severance payments totaling $158,875 and accelerated vesting of one tranche of stock options granted to one of the employees, with such options remaining exercisable for a period of 90 days. The expense of the accelerated vesting of stock options was $24,171 and is included in stock-based compensation for the year ended December 31, 2014. All commitments under these severance agreements have been satisfied.
	Cooperative and License Agreements
	On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “SilverSeal Hydrogel Wound Dressings” and “SilverSeal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years after the initial term. Royalties are to be paid equal to 9.75% of net sales of licensed products. The agreement calls for minimum royalties to be paid each calendar year as follows: 2014 - $400,000; 2015 - $500,000; and 2016 - $600,000. Total royalties charged to selling, general and administrative expense for the years ended December 31, 2014 and 2013 were $400,000 and $200,000, respectively. $395,538 is included in accounts payable as of December 31, 2014 in connection with this agreement.
	Sorbion Distributor Agreement
	On September 23, 2013, the Company entered into a distributor agreement (the “Sorbion Agreement”) with Sorbion GmbH & Co KG, pursuant to which the Company became the exclusive distributor of sorbion sachet S, sorbion sana and new products with hydrokinetic fibers as primary dressings in the United States, Canada and Latin America, subject to certain exceptions. The initial term of the agreement ends on December 31, 2018.
	In order to maintain its exclusivity, the Company must purchase the following minimum amounts, in Euros, of the products for the indicated calendar year:
	Calendar Year		Minimum Annual Purchase Amount
	2014		500,000 Euros
	2015		1,000,000 Euros
	2016		2,500,000 Euros
	2017		4,000,000 Euros
	Since the Company must purchase the minimum amounts in Euros, the equivalent U.S. dollar expenditure will be subject to fluctuations in foreign currency exchange rates. The minimum annual purchase amounts in U.S. Dollars for each calendar year in the period from 2015-2017, based on the exchange rate as of December 31, 2014, are approximately $1,215,480, $3,038,700, and $4,861,920, respectively.
	If the Company fails to purchase products in amounts that meet or exceed the minimum annual purchase amount for a calendar year, it may cure such minimum purchase failure by paying Sorbion in cash an amount equal to the minimum annual purchase amount for such calendar year less the amount the Company paid to Sorbion for the products purchased for such calendar year.  If the Company does not cure a minimum purchase failure with a makeup payment for a calendar year, Sorbion may terminate the Company’s exclusivity with respect to the products and grant the Company non-exclusive rights with respect to the products.  If the Company does not cure a minimum purchase failure for two subsequent calendar years, Sorbion may terminate the agreement.  The Company will not be required to meet the minimal annual purchase amount if Sorbion fails to supply the Company with the products in accordance with the agreement.  Sorbion may also terminate the Company’s exclusivity with respect to the products if the Company does not cure a material breach of the agreement within 30 days. The Company met the minimum annual purchase amount of 500,000 Euros in the year ended December 31, 2014.
	The Company has the right to use the trademarks related to the products. The Company will sell the products under their respective trademarked names and at prices determined by the Company.  Sorbion may determine in its sole discretion the prices of the products sold to the Company, which are subject to change beginning January 1, 2015. The Company will be eligible for certain discounts with respect to the purchase and shipping of the products if its orders of the products are above certain amounts.
	Carolon Distribution Rights Agreement
	In September 2013, the Company entered into an agreement with Carolon Company (“Carolon”) pursuant to which the Company purchased the distribution rights to the sorbion sachet and sana products from Carolon. The Company was committed to pay Carolon an aggregate payment of $400,000 in 12 equal monthly payments beginning November 2013. This transaction was recorded as the purchase of distribution rights and was recorded as an intangible asset, subject to amortization over the remaining useful life of sixty-three months, and a corresponding liability of $400,000. The Company satisfied the $400,000 commitment during the year ended December 31, 2014. The Company is also committed to pay Carolon $50,000 in January 2015 if the Company sold at least $600,000 of sorbion sachet products in the 2014 calendar year. The Company met this obligation and has recorded $50,000 in accrued royalty at December 31, 2014.
	Celgene License, Marketing and Development and Supply Agreement
	In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) with Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”), pursuant to which CCT granted the Company an exclusive, royalty-bearing license in its intellectual property for certain placental based products, including ECMs, an extracellularmatrix derived from the human placenta, and Biovance®, CCT’s proprietary wound coverings produced from decellularized, dehydrated human amniotic membrane, to develop and commercialize ECMs and Biovance in the United States. Following the commencement of commercial sales of the licensed products, the Company will pay CCT annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. The initial term of the License Agreement ends on November 14, 2023, unless sooner terminated pursuant to the termination rights under the License Agreement, and will extend for additional two-year terms unless either party gives written notice within a specified period prior to the end of a term. The License Agreement may be terminated (i) by CCT if the Company or any of its affiliates challenges the validity, enforceability or scope of certain enumerated CCT patents anywhere in the world; (ii) by either party if there is a final decree that a licensed product infringed on the intellectual property of a third party; (iii) by either party for breach of the License Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. In addition, the License Agreement is terminable on a product-by-product basis, and not with respect to the entire License Agreement (i) by CCT in the second year of the License Agreement, and by either CCT or the Company in the third year of the License Agreement and beyond, if the Company fails to meet certain sales thresholds and (ii) by either party upon written notice if outside legal counsel recommends discontinuance of commercialization of a product because of significant safety, legal, or economic risk as a result of a claim, demand or action or as a result of a change in the interpretation of law by a governmental or regulatory authority. The License Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT. In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT.
	In November 2013, the Company also entered into a Supply Agreement (the “Biovance Supply Agreement”) with CCT, pursuant to which CCT shall supply the Company with the Company’s entire requirements of Biovance for distribution and sale in the United States. The Biovance Supply Agreement will be terminated automatically upon the termination of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the Biovance Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. On April 10, 2014, the Company and CCT entered into an amendment to the Biovance Supply Agreement in order to amend the pricing schedule.
	In April 2014, the Company entered into a Supply Agreement (the “ECM Supply Agreement”) with CCT, pursuant to which CCT shall, as soon as reasonably practicable after the date that CCT obtains regulatory clearance or approval in the United States for any of CCT’s extracellular matrix products derived from the human placenta (each an “ECM”), supply and sell to the Company all of the Company’s requirements of ECMs, in finished form and final packaging, for exploitation in the United States under the License Agreement. The ECM Supply Agreement will automatically terminate upon the termination or expiration of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the ECM Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. The ECM Supply Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT.
	Litigation, Claims and Assessments
	The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business.
	On February 27, 2014, ConvaTec Inc. filed suit against the Company and four of its current employees (each a former employee of ConvaTec Inc.), requesting injunctive relief for allegations involving breach of contract, tortious interference with employment agreements, unfair competition and common law conspiracy. On or about February 9, 2015, the parties executed a confidential settlement agreement terminating the litigation on mutually agreeable terms.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]		10	Stockholders’ Equity
	Preferred Stock
	The Company has authorized 1,000,000 shares of preferred stock, $0.001 par value per share, which may be divided into series and with preferences, limitations and relative rights determined by the Board of Directors.
	On October 22, 2013, as amended on November 6, 2013, the Company issued 250,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”) and a five-year warrant to purchase 126,984 shares of common stock at an exercise price of $4.38 per share (the “Investor Warrant”) to an accredited investor in exchange for $1,000,000. The stated value of the Preferred Stock was $4.00 per share and it accrued dividends at the rate of 6% per annum. Each share of Preferred Stock was convertible by the investor at any time into common stock at an initial conversion price of $3.94 per share. In connection with the closing of the sale of the Preferred Stock and Investor Warrant, the Company paid $70,000 in cash fees to the Company’s placement agent (the “Placement Agent”) and issued a five-year warrant to purchase 8,889 shares of common stock at an exercise price of $4.38 per share and a five-year warrant to purchase 8,889 shares of common stock at an exercise price of $4.81 per share to the Placement Agent.
	The Preferred Stock was initially classified as mezzanine (or temporary) equity on the balance sheet, because the Company was obligated to redeem the Preferred Stock on October 21, 2015 if the holders did not elect to convert the Preferred Stock into common stock prior to that date. The Preferred Stock was recorded net of $573,188 discount and issuance costs, which was comprised of $113,906 in issuance costs and $459,285 of discount associated with the issuance of related equity instruments. The $113,906 issuance cost represented $70,000 of cash and the $43,906 value of the warrants issued to the Placement Agent. The $459,282 equity instrument discount was comprised of the $240,507 relative fair value of the Investor Warrant, the $129,396 value of the initial beneficial conversion feature and the $89,379 value of the contingent beneficial conversion feature. The aggregate beneficial conversion feature represented the difference between the $978,268 commitment date value of the Conversion Shares (279,505 shares times the $3.50 closing price of the Company’s common stock on October 22, 2013) and the $759,493 accounting conversion price of the Conversion Shares ($1,000,000 proceeds less the $240,507 relative fair value of the Investor Warrant). On November 19, 2013, the full $459,282 equity instrument discount was recognized as a deemed dividend and the remaining carrying value of the Preferred Stock was reclassified to permanent equity.
	The Investor Warrant will be automatically exercised on the date that the closing price of the common stock equals or exceeds 2.5 times the then-applicable exercise price for a period of sixty consecutive trading days; provided, that, at such time, the Company has an effective registration statement for the resale of the shares of common stock issuable upon exercise of the Investor Warrant (the “Warrant Shares”) or the Warrant Shares may be offered for sale to the public without any volume restrictions. The Investor Warrant is exercisable at any time on a cashless basis.
	Common Stock and Warrant Offerings
	The following table summarizes the common stock and warrant offerings during the years ended December 31, 2014 and 2013:
											Five-Year Warrants
									Common		Investor		Placement Agent
	Issuance		Gross			Issuance			Stock		Warrants		Warrants	Exercise
	Date		Proceeds			Costs			(Shares)		(Shares)		(Shares)	Price
	2/22/13			380,500			-		107,372		107,372		-	$	4.24
	4/11/13			236,000			37,100		66,596		66,596		6,660	$	4.24
	4/22/13			576,000			55,100		162,540		162,540		13,150	$	4.24
	5/31/13			288,000			31,300		81,270		81,270		8,127	$	4.24
	6/28/13			1,976,925			62,632		557,862		557,862		17,674	$	4.24
	11/14/13			6,000,000	[1]		-		1,672,474		836,237		-	$	5.69
	11/18/13			7,000,000			494,000		1,951,220		975,610		136,490	$	5.69
	2013 Total			16,457,425			680,132		4,599,334		2,787,487		182,101
	4/14/14			14,975,003			602,500		2,139,287		427,858		-	$	10.5
	2014 Total			14,975,003			602,500		2,139,287		427,858		-
	Total		$	31,432,428		$	1,282,632		6,738,621		3,215,345		182,101
	[1] See Note 9 – Commitment and Contingencies for details regarding the Celgene License, Marketing, and Development Agreement and Supply Agreement.
	The securities purchase agreement for each of the above financings contain customary representations, warranties and covenants. In addition, the securities purchase agreements for 2013 transactions prior to November 2013 contain a “full ratchet” anti-dilution adjustment provision, pursuant to which, in the event that the Company sells or issues shares of common stock or common stock equivalents at a price (the “Base Price”) lower than $3.54 per share, the Company will be required to issue to each investor, for no additional consideration, a certain number of shares of common stock such that the purchase price paid by such investor under the securities purchase agreement for the number of shares originally held, when divided by the aggregate number of shares originally held and any additional shares issued to such investor, will equal the Base Price. This investor right will terminate for an investor at any time following the nine month anniversary of the final closing under such investor’s securities purchase agreement, if (i) the closing sales price of the common stock for thirty (30) consecutive trading days is at least 200% of the per share purchase price, (ii) the product of (A) the volume weighted average price of the common stock on its principal market and (B) its corresponding daily trading volume, each as reported by Bloomberg L.P., equals or exceeds $50,000 for such thirty (30) consecutive trading days and (iii) the investor shares that were acquired by investors who are not our affiliates are eligible for unrestricted sale pursuant to Rule 144 under the Securities Act of 1933, as amended on the Company’s principal market from the six month anniversary of the final closing under the securities purchase agreement through at least the nine month anniversary of such final closing. Each warrant is exercisable immediately for cash. In addition, in the event that there is no effective registration statement registering, or no current prospectus available for, the resale of the shares of common stock issuable upon exercise of a warrant at any time following the one year anniversary of the issuance date of such warrant, such warrant may also be exercised by way of a cashless exercise. The warrants also contain customary provisions that protect their holders against dilution by adjustment of the purchase price in certain events such as stock dividends, stock splits and other similar events.
	2011 Plan
	The Company maintains the 2011 Long-Term Incentive Plan (the “2011 Plan”) that provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. A total of 1,828,571 shares of common stock have been authorized for issuance under the 2011 Plan, of which, as of December 31, 2014, 15,179 shares were available for future issuances.
	2014 Plan
	On April 10, 2014 and June 5, 2014, the Company’s Board of Directors and the Company’s shareholders, respectively, approved the 2014 Long-Term Incentive Plan (the “2014 Plan”). The 2014 Plan provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. A total of 2,000,000 shares of common stock have been authorized for issuance under the 2014 Plan, of which, as of December 31, 2014, 1,742,000 shares were available for future issuances.
	Stock-Based Compensation
	The following table summarizes stock-based compensation expense:
			Year Ended December 31,
			2014			2013
	Options		$	7,815,411		$	3,948,025
	Warrants			210,160			172,913
	Restricted stock units			180,715			83,836
	Restricted stock			2,523,760			1,309,087
	Total stock-based compensation		$	10,730,046		$	5,513,861
	For the year ended December 31, 2014, $199,781 of stock-based compensation is included in cost of revenues and $10,530,265 is included in selling, general and administrative expenses in the consolidated statements of operations. For the year ended December 31, 2013, $5,513,861 of stock-based compensation is included in selling, general and administrative expenses in the consolidated statements of operations.
	Restricted Stock
	The following table summarizes the restricted stock issued as compensation during the years ended December 31, 2014 and 2013:
	Issuance		Grantee		Shares		Vesting			Grant Date
	Date		Type		Issued		Term			Value
	5/24/13		Consultant		2,286		Immediate				7,000
	6/28/13		Fmr. Officer		186,165		Immediate				570,130
	7/1/13		Consultant		16,429		Immediate				50,312
	10/15/13		Consultant		3,265		Immediate				10,000
	11/11/13		Fmr. Officer		186,165		Immediate				651,578
	11/14/13		Consultant		2,875		Immediate				10,063
	12/12/13		Employee		21,614		One year				150,001	[1]
	12/24/13		Consultant		1,409		Immediate				10,004
			2013 - Restricted Stock - Total		420,208						1,459,088
	1/6/14		Officer		369,395		[2]			$	2,582,072
	1/17/14		Consultant		1,107		Immediate				10,007
	1/27/14		Consultant		13,000		Immediate				118,300
	3/6/14		Employee		8,300		[3]				74,700
	3/9/14		Consultant		1,108		Immediate				10,005
	3/21/14		Consultant		1,136		Immediate				10,008
	4/2/14		Consultant		1,219		Immediate				10,008
	5/29/14		Consultant		1,000		Immediate				7,000
	6/16/14		Consultant		1,525		Immediate				10,004
	6/18/14		Consultant		1,558		Immediate				10,002
	7/1/14		Consultant		1,743		Immediate				10,005
			2014- Restricted Stock - Total		401,091					$	2,852,111
	[1]	Shares forfeited during 2013. The Company did not record any stock-based compensation expense during 2013 related to the issuance.
	[2]	Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter.
	[3]	2,425 shares vest on each of March 6, 2014 and April 1, 2014. 1,725 shares vest on each of April 1, 2015 and April 1, 2016.
On March 14, 2014, in connection with the resignation of the chief executive officer of a wholly-owned subsidiary of the Company, the Company accelerated the vesting of 17,688 RSUs that, prior to the modification, contained performance conditions which, for accounting purposes, were deemed improbable of being achieved. As a result, the Company recorded stock-based compensation expense of $157,069 during the year ended December 31, 2014, which represented the modification date value of the modified RSUs.
As of December 31, 2014, there was $327,448 of unrecognized stock-based compensation expense related to restricted stock which will be amortized over a weighted average period of 0.6 years.
A summary of restricted stock award activity during the years ended December 31, 2014 and 2013 is presented below:
				Weighted
				Average			Total Grant
		Number of		Grant Date			Date Fair
		Shares		Fair Value			Value
Non-vested, December 31, 2012		70,753		$	2.19		154,773
Granted		420,208		$	3.47		1,459,088
Vested		-433,971		$	3.19		-1,386,473
Forfeited		-21,614		$	6.94		-150,001
Non-vested, December 31, 2013		35,376		$	2.19		77,387
Granted		401,091		$	7.11		2,852,111
Vested		-248,318		$	6.47		-1,607,402
Forfeited		-			-		-
Non-vested, December 31, 2014		188,149		$	7.03		1,322,096
Warrants
See Common Stock and Warrant Offerings above for details of warrants issued to investors and placement agents in connection with equity offerings.
On July 11, 2013, the Company issued to a consultant a five-year warrant to purchase 6,857 shares of common stock at an exercise price of $4.38 per share, which will vest and become exercisable in 12 equal monthly installments over the first year from the date of issuance. The aggregate grant date value was $14,640.
Between October 28 and November 12, 2013, the Company issued to various consultants five-year warrants to purchase an aggregate of 68,571 shares of common stock at exercise prices ranging from $4.38 to $5.69 per share. The warrants vest in twelve equal monthly installments from the date of issuance. The aggregate grant date value was $168,255.
During the year ended December 31, 2013, the Company issued an aggregate of  261,030 shares of common stock to several holders of warrants who elected to exercise warrants to purchase an aggregate of  371,429 shares of common stock on a "cashless" basis under the terms of the warrants. The warrants had exercise prices of $3.02 per share (125,714 gross shares) and $2.19 per share (245,715 gross shares). The aggregate intrinsic value of the warrants exercised was $2,167,657.
On April 11, 2014, the Company entered into a letter agreement with certain of the holders of warrants to purchase shares of the Company’s common stock that were granted pursuant to that certain securities purchase agreement, dated November 18, 2013, by and among the Company and the investors signatory thereto. The Company received approximately $5,293,000 from the exercising holders upon the exercise of the warrants, and the Company issued a total of 930,313 shares of common stock to the exercising holders pursuant to the terms of the warrants. In connection with the holders exercising their warrants pursuant to the letter agreement, the Company paid $265,000 in placement agent fees and $2,500 of professional fees for the escrow agent, both of which were deducted from gross proceeds. The warrants, which were exercised at a price of $5.69 per share, had an aggregate intrinsic value of $1,544,320.
During the year ended December 31, 2014, in addition to the exercised warrants discussed above, the Company issued an aggregate of 258,295 shares of common stock to several holders of warrants who elected to exercise warrants to purchase an aggregate of 400,137 shares of common stock (353,137 shares on a "cashless" basis under the terms of the warrants and 47,000 shares for cash proceeds of $199,280). The warrants had exercise prices of $4.24 per share (241,060 gross shares), $3.02 per share (65,362 gross shares) and $2.19 per share (93,715 gross shares). Excluding the value of the warrants discussed in the paragraphs above, the aggregate intrinsic value of the warrants exercised was $1,971,481.
In applying the Black-Scholes option pricing model to warrants issued, the Company used the following weighted average assumptions:
		Year Ended December 31,
		2014		2013
Risk free interest rate		1.61	%	1.27	%
Expected term (years)		5		5
Expected volatility		102.63	%	99.59	%
Expected dividends		0	%	0	%
The risk-free interest rate is based on rates of treasury securities with the same expected term as the warrants. The expected term used for warrants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future.
There were no compensatory warrants issued during the year ended December 31, 2014. The weighted average estimated fair value of the compensatory warrants issued during the year ended December 31, 2013 was $2.42 per share.
As of December 31, 2014, there was no unrecognized stock-based compensation expense related to compensatory warrants.
A summary of the warrant activity, including common stock purchase warrants, during the years ended December 31, 2014 and 2013 is presented below:
				Weighted			Weighted
				Average			Average
		Number of		Exercise			Remaining
		Warrants		Price			Life in Years		Intrinsic Value
Outstanding, December 31, 2012		1,004,208		$	3.94
Issued		3,189,778			5.15
Exercised		-371,429			1.01
Cancelled		-			-
Outstanding, December 31, 2013		3,822,557		$	5.12
Issued		427,858			10.5
Exercised		-1,330,450			5.03
Cancelled		-244,844			7.88
Outstanding, December 31, 2014		2,675,121		$	5.76		3.7		$	1,515,872
Exercisable, December 31, 2014		2,675,121		$	5.76		3.7		$	1,515,872
The following table presents information related to warrants at December 31, 2014:
Warrants Outstanding					Warrants Exercisable
					Weighted
					Average
			Outstanding		Remaining		Exercisable
			Number of		Life in		Number of
Exercise Price			Warrants		Years		Warrants
$	2.19		108,572		2.8		108,572
	3.02		74,286		2.1		74,286
	3.5		2,286		2.3		2,286
	4.24		780,191		3.4		780,191
	4.38		188,444		3.8		188,444
	4.81		8,889		3.8		8,889
	5.69		1,040,880		3.9		1,040,880
	7		18,286		0.4		18,286
	8.75		25,429		0.6		25,429
	10.5		427,858		4.3		427,858
			2,675,121		3.7		2,675,121
As of December 31, 2014, five-year warrants to purchase an aggregate of 75,429 shares of common stock at an exercise price of $2.19 per share were deemed to be a derivative liability. See Note 14– Fair Value Measurement.
Stock Options
Options - 2013 Grants
During 2013, options to purchase an aggregate of  3,319,421 shares of common stock at exercise prices ranging from $3.28 to $10.94 (with a weighted average exercise price of $6.37 per share) with an aggregate grant date value of $9,375,010 were granted to directors, employees and consultants.  Of the above, options to purchase an aggregate of 302,084 and 3,017,337 shares of common stock were granted pursuant to the 2011 Plan and not pursuant to a plan, respectively. Most of the 2013 grants had five or ten year terms and vested between immediately or within three years.  In general, the grant date value is being amortized over the vesting term.
Details of the grants with the more significant grant date values are as follows:
	-1	On December 20, 2013, a ten-year option to purchase 730,535 shares of common stock with an aggregate grant date value of $3,826,039 was granted to an officer of the Company. The options are scheduled to vest and become exercisable at $6.82 per share as follows: (i) 81,171 shares on January 1, 2014 and (ii) 81,170 or 81,171 shares on each of the next eight succeeding quarterly anniversaries of the first vesting date.
	-2	On July 22, 2013, a 9.5-year option to purchase 622,170 shares of common stock with an aggregate grant date value of $1,556,984 was granted to a director. The options were scheduled to vest and become exercisable as follows: (i) options to purchase 207,290 shares of common stock at $6.56 per share are currently deemed probable of vesting upon the meeting of certain performance criteria; (ii) options to purchase 207,290 shares of common stock at $8.75 per share are currently deemed probable of vesting upon the meeting of certain performance criteria; (iii) options to purchase 207,290 shares of common stock at $10.94 per share are also currently deemed probable of vesting upon the meeting of certain performance criteria. In conjunction with this grant, certain outstanding options with as yet unmet 2013 performance conditions held by this director were cancelled, as follows: (a) options to purchase 106,057 shares of common stock at $6.56 per share; (b) options to purchase 114,286 shares of common stock at $8.75 per share; and (c) options to purchase 57,142 shares of common stock at $8.75 per share.
	-3	On February 4, 2013, a ten-year immediately vested option to purchase 279,227 shares of common stock at an exercise price of $3.18 per share with an aggregate grant date value of $684,107 was granted to an officer of the Company.
Options - 2014 Grants
During 2014, ten-year options to purchase an aggregate of 1,273,520 shares of common stock at exercise prices ranging from $3.89 to $9.05 (with a weighted average exercise price of $7.00 per share) with an aggregate grant date value of $7,131,453 were granted to directors, employees and consultants. Of the above, options to purchase an aggregate of 736,500, 268,000 and 269,020 shares of common stock were granted pursuant to the 2011 Plan, 2014 Plan and not pursuant to a plan, respectively. Most of the 2014 grants vest over three years on the anniversaries of the grant date. In general, the grant date value is being amortized over the vesting term.
Details of the grants with the more significant grant date values are as follows:
	-1	On January 6, 2014, a ten-year option to purchase 91,520 shares of common stock with a grant date value of $506,355 was granted to an employee of the Company. The option is scheduled to vest and become exercisable at $6.99 per share as follows: (i) 22,800 shares vested immediately on the date of grant (ii) 22,880 shares on each of the next three anniversaries of the date of grant.
	-2	On March 6, 2014, a ten-year option to purchase 70,000 shares of common stock at an exercise price of $9.00 per share was granted to three employees of the Company (options to purchase 210,000 shares of common stock in the aggregate). The options had an aggregate grant date value of $1,517,153. Each option is scheduled to vest and become exercisable in thirds on each of the next three anniversaries of the date of grant.
Options - Summary Data
In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
		Year Ended December 31,
		2014		2013
Risk free interest rate		1.89	%	1.4	%
Expected term (years)		6.08		5.55
Expected volatility		101.93	%	99.78	%
Expected dividends		0	%	0	%
The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. The Company uses the "simplified method" to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future.
Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to options at annual rates ranging from 0% to 5% for options outstanding at December 31, 2014.
The weighted average estimated fair value of the options granted during the years ended December 31, 2014 and 2013 was $5.60 and $2.80 per share, respectively.
During the year ended December 31, 2014, the Company issued an aggregate of  306,403 shares of common stock to several holders of options who elected to exercise options to purchase an aggregate of  333,876 shares of common stock (57,143 shares on a "cashless" basis under the terms of the options and 276,733 shares for cash proceeds of $1,371,913). The options had exercise prices of $4.38 per share (252,217 gross shares), $5.47 per share (11,428 gross shares), $6.34 per share (22,857 gross shares) and $6.56 per share (47,374 gross shares). The aggregate intrinsic value of the options exercised was $942,584 for the year ended December 31, 2014.
As of December 31, 2014, there was $5,292,913 of unrecognized stock-based compensation expense related to stock options which will be amortized over a weighted average period of 1.6 years, of which $156,639 is subject to non-employee mark-to-market adjustments.
A summary of the stock option activity during the years ended December 31, 2014 and 2013 is presented below:
							Weighted
				Weighted			Average
				Average			Remaining
		Number of		Exercise			Life in
		Options		Price			Years		Intrinsic Value
Outstanding, December 31, 2012		2,333,822		$	6.56
Granted		3,319,421			6.37
Exercised		-			-
Forfeited		-667,657			6.96
Outstanding, December 31, 2013		4,985,586		$	6.47
Granted		1,273,520			7
Exercised		-333,876			4.86
Forfeited		-1,107,570			7.19
Outstanding, December 31, 2014		4,817,660		$	6.56		7.9		$	1,819,594
Exerciseable, December 31, 2014		2,370,451		$	5.64		6.9		$	1,562,512
The following table presents information related to stock options at December 31, 2014:
		Options Outstanding					Options Exercisable
		Weighted								Weighted
		Average			Outstanding					Average		Exercisable
Range of		Exercise			Number of		Weighted Average			Remaining		Number of
Exercise Price		Price			Options		Exercise Price			Life in Years		Options
$3.28-$3.99		$	3.4		433,971		$	3.36		8.3		403,971
$4.00-$4.99			4.42		1,112,401			4.38		4.3		845,619
$5.00-$5.99			5.43		309,427			5.56		6.9		116,296
$6.00-$6.99			6.77		1,528,177			6.74		8.7		596,225
$7.00-7.99			7.75		31,000			-		-		-
$8.00-$8.99			8.75		807,565			8.75		8		359,164
$9.00-$9.99			9.01		331,500			9		9.2		11,232
$10.00-26.69			10.96		263,619			11.05		8.2		37,944
					4,817,660							2,370,451

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	11	Income Taxes
	The Company files corporate income tax returns in U.S. federal, state and local jurisdictions, including Pennsylvania, and has tax returns subject to examination by tax authorities generally beginning in the year ended December 31, 2011 and through December 31, 2014. However, to the extent we utilize our net operating loss (“NOL”) carryforwards in the future, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities of the future period tax return in which the attribute is utilized.
			For The Years Ended
			December 31,
			2014			2013
	Federal:
	Current		$	-		$	-
	Deferred			10,000			10,000
	State and local:
	Current			-			-
	Deferred			4,000			-1,000
	Income tax provision		$	14,000		$	9,000
	For the years ended December 31, 2014 and 2013, the expected tax expense based on the federal statutory rate reconciled with the actual tax expense is as follows:
			For The Years Ended
			December 31,
			2014		2013
	U.S. federal statutory rate		34	%	34	%
	State tax rate, net of federal benefit		4.2	%	5.9	%
	Permanent Differences
	- Change in fair value of warrant liability		-0.1	%	-3.3	%
	- Other		-1.6	%	-1.7	%
	Adjustments to deferred taxes		-13.8	%	0	%
	Change in valuation allowance		-22.8	%	-34.9	%
	Income tax provision		-0.1	%	0	%
	As of December 31, 2014 and 2013, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following:
			For The Years Ended
			December 31,
			2014			2013
	Deferred tax assets:
	Net operating loss carryforwards		$	18,844,000		$	10,703,000
	Stock-based compensation			5,028,000			2,825,000
	Intangible assets			-			4,059,000
	Accruals			579,000			326,000
	Other			244,000			230,000
	Total deferred tax assets			24,695,000			18,143,000
	Valuation allowance			-24,081,000			-17,607,000
	Deferred tax assets, net of valuation allowance			614,000			536,000
	Deferred tax liabilities:
	Property and equipment			-515,000			-536,000
	Intangible assets			-99,000			-
	Goodwill			-67,000			-53,000
	Total deferred tax liabilities			-681,000			-589,000
	Net deferred tax liabilities		$	-67,000		$	-53,000
	For the years ended December 31, 2014 and 2013, the Company had approximately $50,043,000 and $27,408,000 of federal NOL carryovers, respectively, which substantially begin to expire in 2022 and through 2034. The company also has state NOL carryovers in multiple jurisdictions, including most materially in Pennsylvania, $11,648,000 and $8,202,000, and in Florida, $7,850,000 and $7,226,000, as of December 31, 2014 and December 31, 2013, respectively. The net operating loss carryovers may be subject to annual limitations under Internal Revenue Code Section 382, and similar state provisions, should there be a greater than 50% ownership change as determined under the applicable income tax regulations. The amount of the limitation would be determined based on the value of the Company immediately prior to the ownership change and subsequent ownership changes could further impact the amount of the annual limitation. An ownership change pursuant to Section 382 may have occurred in the past or could happen in the future, such that the NOLs available for utilization could be significantly limited. The Company will perform a Section 382 analysis in the near future to determine whether its NOLs will be subject to an annual limitation. On May 5, 2014 the Company acquired the equity interests of Choice (see Note 3 – Acquisitions) and, accordingly, the Company believes the Choice NOL carryforwards as of that date are subject to Section 382 limitations. The amount of federal NOL carryforwards as of December 31, 2014 disclosed above do not include $2,498,000 of Choice NOL carryforwards that the Company has estimated will expire unutilized pursuant to this limitation.
	In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the future generation of taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The deferred tax liability related to goodwill cannot be used in this determination since goodwill is considered to be an asset with an indefinite life for financial reporting purposes. After consideration of all the evidence, both positive and negative, management has recorded a full valuation allowance against net deferred tax assets at December 31, 2014 and December 31, 2013 because management has determined that it is more likely than not that these deferred tax assets will not be realized. The valuation allowance increased by $6,474,000 and $7,677,000 during the years ended December 31, 2014 and December 31, 2013, respectively, primarily related to increases in NOL carryforwards.

Related_Party

Related Party	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	12	Related Party
	On February 15, 2013, a subscription receivable of $20,000 was received from a director in connection with a private placement.
	On February 22, 2013, the Company issued to four directors and an affiliate of a director, in the aggregate, (i) 76,190 shares of common stock and (ii) five year warrants to purchase, in the aggregate, up to 76,190 shares of common stock at an exercise price of $4.24 per share, in exchange for aggregate consideration of $270,000.
	On June 28, 2013, the Company issued to five directors, in the aggregate, (i) 231,393 shares of common stock and (ii) five year warrants to purchase, in the aggregate, up to  231,393 shares of common stock at an exercise price of $4.24 per share, in exchange for aggregate consideration of $820,000.
	On November 14, 2013, the Company entered into a stock purchase agreement with Celgene, pursuant to which the Company sold, on November 18, 2013, an aggregate of 1,672,474 shares of common stock and a five year warrant to purchase an aggregate of 836,237 shares of common stock at an exercise price of $5.69 per share, in exchange for aggregate consideration of $6,000,000.
	On January 6, 2014, the Company entered into an option cancellation and release agreement with two former directors, pursuant to which each of the parties agreed to cancel options previously granted to purchase 278,096 shares of common stock of the Company at exercise prices ranging from $6.34 to $9.19.  In exchange for the cancellation of the options, the Company granted each individual 194,667 shares of common stock of the Company pursuant to the 2011 Plan. The incremental expense for the exchange was $98,915 and is included in stock-based compensation for the year ended December 31, 2014.
	On April 14, 2014, the Company entered into a securities purchase agreement with Celgene, pursuant to which the Company issued (i) 714,286 shares of common stock at $7.00 per share and (ii) five year warrants to purchase 142,857 shares of common stock at an exercise price of $10.50 per share, in exchange for aggregate consideration of approximately $5,000,000.

Concentration_of_Risk

Concentration of Risk	12 Months Ended
	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	13	Concentration of Risk
	Revenue for the years ended December 31, 2014 and 2013, and accounts receivable as of December 31, 2014 from our largest customers, both contract manufacturing customers, were as follows:
			2014
	Customer		% of Total Revenue		Accounts Receivable
	A		23	%	9	%
			2013
	Customer		% of Total Revenue		Accounts Receivable
	A		51	%	51	%
	B		16	%	0	%

Fair_Value_Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	14	Fair Value Measurement
	On December 2, 2013, warrants to purchase an aggregate of 228,572 shares of common stock were exercised. These warrants had an aggregate exercise date fair value of $1,505,770, which was credited to equity. The Company recorded a loss on the change in fair value of these warrants of $1,141,964 during the year ended December 31, 2013. The Company recomputed the fair value of these warrants using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 99.44%, risk-free rate of 1.01%, expected term of 3.94 years, and expected dividends of 0.00%.
	On December 31, 2013, the Company recomputed the fair value of its warrant liability of warrants to purchase an aggregate of 152,000 shares of common stock as $933,465 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 102.63%, risk-free rate of 1.27%, expected term of 3.86 years, and expected dividends of 0.00%. The Company recorded a loss on the change in fair value of these warrant liabilities of $691,534 during the year ended December 31, 2013.
	During the year ended December 31, 2014, warrants to purchase an aggregate of 82,971 shares of common stock were exercised. These warrants had an aggregate exercise date fair value of $672,632 which was credited to equity. The Company recorded a loss on the change in fair value of these warrants of $202,393 during the year ended December 31, 2014. The Company recomputed the fair value of these warrant using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 102.63%, risk-free rate of 1.19%-1.22%, expected term of 3.78-3.81 years, and expected dividends of 0.00%.
	On December 31, 2014, the Company recomputed the fair value of its remaining warrant liability of warrants to purchase an aggregate of 75,429 shares of common stock as $304,223 using the Binomial option pricing model (Level 3 inputs) using the following assumptions: expected volatility of 98.25%, risk-free rate of 1.10%, expected term of 2.86 years, and expected dividends of 0.00%. The Company recorded a gain on the change in fair value of these warrant liabilities of $159,003 during the year ended December 31, 2014.
	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis:
			December 31,
	Warrant Liabilities		2014		2013
	Beginning balance as of January 1,		$	933,465	$	605,737
	Change in fair value of warrant liability			43,390		1,833,498
	Value of warrants exercised			-672,632		-1,505,770
	Ending balance as of December 31,		$	304,223	$	933,465
	Contingent Consideration
	Beginning balance as of January 1, 2014		$	-
	Fair value of contingent consideration			2,700,000
	Change in fair value of contingent consideration			231,598
	Ending balance as of December 31, 2014		$	2,931,598
	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows:
			December 31, 2014
			Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities		$	-	$	-	$	304,223
	Contingent consideration			-		-		2,931,598
	Total liabilities		$	-	$	-	$	3,235,821
			December 31, 2013
			Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities		$	-	$	-	$	933,465
	Total liabilities		$	-	$	-	$	933,465
	Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that was classified as Level 3 in the table above was estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s chief financial officer and are approved by the chief executive officer.

Defined_Contribution_Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	15	Defined Contribution Plan
	The Company maintains the Alliqua, Inc. 401(k) Profit Sharing Plan and Trust (“Plan”) in accordance with the provisions of Section 401(k) of the Internal Revenue Code (“Code”).  The Plan covers substantially all full-time employees of the Company.  Participants may contribute up to 100% of their total compensation to the Plan, not to exceed the limit as defined in the Code. The Company does not currently provide any Company match, therefore no expenses were recorded during the years ended December 31, 2014 or 2013.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	16	Subsequent Events
	On February 2, 2015 the Company entered in an Agreement and Plan of Merger (‘the Merger Agreement”) with Celleration, Inc. The Merger Agreement provides for an initial aggregate purchase price of $30,415,000 payable in equal amounts of cash and the Company’s common stock. In connection with the Merger Agreement, the Company received a commitment letter from a lender in which the lender has committed to provide the Company with a senior, secured term loan facility in the amount of $15,500,000, pursuant to the terms of the commitment letter. The Company expects to use the proceeds from this loan facility to provide the capital for the upfront cash portion associated with the consummation of the Merger Agreement. The Merger Agreement may be terminated by either party if the merger is not completed by May 31, 2015, provided that the Company may extend that date to July 31, 2015 in certain circumstances so long as the Company can provide Celleration with a $1,000,000 loan by May 15, 2015. The Merger Agreement also contains customary termination provisions which would require the Company to pay a termination fee of $3,000,000, less any amounts loaned to Celleration, if the Merger Agreement is terminated by (i) the Company or Celleration for the Company’s failure to obtain the required approval of the Company’s stockholders or (ii) Celleration for the Company’s failure to secure the required financing. Celleration is required to pay the Company a termination fee of $4,000,000 if Celleration terminates the Merger Agreements in order to accept a superior proposal as defined in the Merger Agreement.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates in the Financial Statements
	The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles and goodwill. Actual results could differ from the estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company’s balance of cash and cash equivalents at December 31, 2014 and 2013 consisted principally of bank deposits. From time to time, the Company’s cash account balances may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation guarantee limit. The Company reduces its exposure to credit risk by maintaining its cash deposits with major financial institutions and monitoring their credit ratings.
Receivables, Policy [Policy Text Block]	Accounts Receivable
	Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company considers the following factors when determining the collectability of specific customer accounts: customer credit-worthiness, past transaction history with the customer, current economic industry trends, and changes in customer payment terms. The Company’s accounts receivable balance is a result of product sales and contract manufacturing. These receivables have historically been paid timely.  Due to the nature of the accounts receivable balance, the Company believes there is no significant risk of collection.  If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, allowances for doubtful accounts would be required.
Inventory, Policy [Policy Text Block]	Inventory
	Inventory is valued at the lower of cost or market on a first-in, first-out basis. Reserves for inventory obsolescence are based on expiration date and are utilized to account for slow-moving inventory. At December 31, 2014 and 2013, the Company had reserves for obsolete inventory of $1,094 and $76,580, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	Improvements and Equipment
	Improvements and equipment are recorded at cost. Depreciation of equipment is computed utilizing the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed utilizing the straight-line method over the shorter of the remaining lease term or estimated useful life. Repairs and maintenance costs are expensed as incurred. Additions and betterments are capitalized.
In Process Research and Development, Policy [Policy Text Block]	Acquired In-Process Research and Development
	In-process research and development (“IPR&D”) represents the fair value assigned to incomplete research projects that the Company acquires through business combinations which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. During the year ended December 31, 2013, we recognized impairment of our HepaMate™ patented biotech technologies IPR&D of $8,100,000 as we believed there were impairment triggering events and circumstances which warranted an evaluation of certain indefinite-lived intangible assets.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill and Other Intangible Assets
	The Company accounts for goodwill and intangible assets in accordance with the accounting guidance which requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. The Accounting Standards Codification (“Codification”) requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment). Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgment is required to estimate the fair value of reporting units which includes estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment.
	When testing goodwill for impairment, the Company may assess qualitative factors for some or all of its reporting units to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment for some or all of our reporting units and perform a detailed quantitative test of impairment (step 1). If the Company performs the detailed quantitative impairment test and the carrying amount of the reporting unit exceeds its fair value, the Company would perform an analysis (step 2) to measure such impairment. In 2014, the Company first performed a qualitative assessment to identify and evaluate events and circumstances to conclude whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount. Based on the Company’s qualitative assessments, the Company concluded that a positive assertion can be made from the qualitative assessment that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount. In accordance with the Codification, the Company reviews the carrying value of its intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group, if any, exceeds its fair market value. No impairment was deemed to exist as of December 31, 2014.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Subject to Amortization
	The Company amortizes intangible assets with finite lives over their estimated useful lives and reviews them for impairment annually or whenever impairment exists. The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. As of December 31, 2014, Company management believed that no revision to the remaining useful lives or write-down of the Company’s long-lived assets was required, and similarly, no such revisions were required for the year ended December 31, 2014.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments
	The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments.
	Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows:
	Level 1: Observable prices in active markets for identical assets and liabilities.
	Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities.
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title and risk of loss have passed to the customer, there is a fixed or determinable sales price, and collectability of that sales price is reasonably assured. Deposits received on product orders are recorded as deferred revenue until revenues are generally earned when the products are shipped to customers.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	Cost of Goods Sold and Selling, General and Administrative Expenses
	Costs associated with the production and procurement of product are included in cost of goods sold, including shipping and handling costs such as inbound freight costs, purchasing and receiving costs, inspection costs and other product procurement related charges. All other expenses, excluding interest and income taxes, are included in selling, general and administrative expenses, as the predominant expenses associated therewith are general and administrative in nature.
Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block]	Advertising Expenses
	Advertising and marketing costs are expensed as incurred. Advertising expenses for the years ended December 31, 2014 and 2013 were $1,607,016 and $298,860, respectively.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling
	Certain shipping and handling costs are paid for by the Company. Shipping and handling costs amounted to approximately $52,884 and $23,523 as of December 31, 2014 and 2013, respectively, and are included in cost of revenues.
Income Tax, Policy [Policy Text Block]	Income Taxes
	The Company accounts for income taxes pursuant to the asset and liability method which requires us to recognize current tax liabilities or receivables for the amount of taxes we estimate are payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts and their respective tax bases of assets and liabilities and the expected benefits of net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible.
	The Company adopted the provisions of Accounting Standards Codification Topic 740 (“ASC 740”) related to the accounting for uncertainty in income taxes recognized in an enterprise's consolidated financial statements. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns.
	The benefit of tax positions taken or expected to be taken in the Company's income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryover or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. Interest costs and related penalties related to unrecognized tax benefits are required to be calculated, if applicable. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses. No interest or penalties were recorded during the years ended December 31, 2014 and 2013. As of December 31, 2014 and December 31, 2013, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.
Common Stock Purchase Warrant [Policy Text Block]	Common Stock Purchase Warrants
	The Company assesses classification of common stock purchase warrants at each reporting date to determine whether a change in classification between assets and liabilities or equity is required.  The Company’s free standing derivatives consist of warrants to purchase common stock that were issued pursuant to a securities purchase agreement on November 8, 2012.  The Company evaluated the common stock purchase warrants to assess their proper classification in the consolidated balance sheet and determined that the common stock purchase warrants contain exercise reset provisions.  Accordingly, these instruments have been classified as warrant liabilities in the accompanying consolidated balance sheets as of December 31, 2014 and 2013.  The Company re-measures warrant liabilities at each reporting and exercise date, with changes in fair value recognized in earnings for each reporting period.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period services are required to be provided in exchange for the award, usually the vesting period. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award. Stock-based compensation expense is reflected within cost of revenues and operating expenses in the consolidated statements of operations. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Common Share
	Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during the periods presented. Common stock equivalents, consisting of warrants, stock options, non-vested restricted stock units (“RSUs”), and non-vested shares of restricted stock, were not included in the calculation of the diluted loss per share because their inclusion would have been anti-dilutive.
	The total common shares issuable upon the exercise of stock options, warrants, non-vested RSUs and non-vested restricted stock are as follows:
		As of December 31,
		2014	2013
	Stock options	4,817,660	4,985,586
	Warrants	2,675,121	3,822,557
	Non-vested restricted stock units	-	35,376
	Non-vested restricted stock	188,149	-
	Total	7,680,930	8,843,519

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The total common shares issuable upon the exercise of stock options, warrants, non-vested RSUs and non-vested restricted stock are as follows:
		As of December 31,
		2014	2013
	Stock options	4,817,660	4,985,586
	Warrants	2,675,121	3,822,557
	Non-vested restricted stock units	-	35,376
	Non-vested restricted stock	188,149	-
	Total	7,680,930	8,843,519

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The Company’s allocation of purchase price for this acquisition is included in the table below, which summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition:
	Consideration:
	Common stock	$	1,992,854
	Cash paid		2,000,000
	Fair value of contingent consideration		2,700,000
	Total consideration		6,692,854
	Cash		474
	Inventory		396,961
	Other assets		11,587
	Tradenames		111,000
	Technology		2,396,000
	Customer relationships		176,000
	Goodwill		3,674,326
	Other liabilities		-73,494
	Net assets acquired	$	6,692,854
Business Acquisition, Pro Forma Information [Table Text Block]	The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisitions had actually occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future.
		Pro forma Results for the
		Year Ended December 31,
		2014		2013
	Revenues	$	5,475,959	$	3,593,933
	Net loss	$	-25,522,302	$	-22,713,859

Inventory_Tables

Inventory (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following:
		December 31,
		2014		2013
	Raw materials	$	197,514	$	174,176
	Work in process		489,431		57,030
	Finished goods		725,897		346,843
	Less: Inventory reserve		-1,094		-76,580
	Total	$	1,411,748	$	501,469

Improvements_and_Equipment_net1

Improvements and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Improvements and equipment consist of the following:
			December 31,
		Useful Life	2014		2013
		(Years)
	Machinery and equipment	10	$	2,869,453	$	2,869,453
	Office furniture and equipment	10-Mar		51,439		44,844
	Leasehold improvements	(A)		228,021		228,021
				3,148,913		3,142,318
	Less: Accumulated depreciation and amortization			-1,714,886		-1,397,070
	Improvements and equipment, net		$	1,434,027	$	1,745,248
	(A) Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	The gross carrying amount and accumulated amortization of intangible assets as of December 31, 2014 and 2013 are as follows:
				December 31, 2014
		Useful Life		Gross		Accumulated				Net
										Carrying
		(Years)		Amount		Amortization		Impairment		Amount
	Technology	10		$	5,396,000	$	-1,934,733	$	-	$	3,461,267
	Customer relationships	12-Sep			776,000		-308,871		-		467,129
	Distribution rights	5.27			400,000		-96,880		-		303,120
	Tradename	3			111,000		-24,667		-		86,333
	Non-compete	1			208,333		-138,889		-		69,444
				$	6,891,333	$	-2,504,040	$	-	$	4,387,293
				December 31, 2013
		Useful Life		Gross		Accumulated				Net
										Carrying
		(Years)		Amount		Amortization		Impairment		Amount
	In process research and development			$	8,100,000	$	-	$	-8,100,000	$	-
	Technology	10			3,000,000		-1,475,000		-		1,525,000
	Customer relationships	12			600,000		-245,834		-		354,166
	Distribution rights	5.27			400,000		-20,689		-		379,311
				$	12,100,000	$	-1,741,523	$	-8,100,000	$	2,258,477
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Amortization expense in each of the five years and thereafter subsequent to December 31, 2014 related to the Company’s intangible assets is expected to be as follows:
		Expected
		Amortization
		Expense
	2015		791,790
	2016		722,346
	2017		697,679
	2018		683,704
	2019		334,156
	Thereafter		1,157,618
	Total	$	4,387,293

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consist of the following:
		December 31,
		2014		2013
	Salaries, benefits and incentive compensation	$	1,528,229	$	1,036,771
	Professional fees		228,426		83,317
	Royalty fees		100,537		-
	Inventory		-		127,786
	Deferred revenue		78,523		39,000
	Deferred lease incentive liability		8,337		8,337
	Other		123,807		44,846
	Total accrued expenses and other current liabilities	$	2,067,859	$	1,340,057

Operating_Leases_Tables

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2014
Leases, Operating [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases in each of the five years and thereafter subsequent to December 31, 2014 are as follows:
	2015	$	206,250
	2016		207,309
	2017		207,405
	2018		207,405
	2019		207,405
	Thereafter		1,261,714
	Total	$	2,297,488

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Long-term Purchase Commitment [Table Text Block]	In order to maintain its exclusivity, the Company must purchase the following minimum amounts, in Euros, of the products for the indicated calendar year:
	Calendar Year	Minimum Annual Purchase Amount
	2014	500,000 Euros
	2015	1,000,000 Euros
	2016	2,500,000 Euros
	2017	4,000,000 Euros

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes the common stock and warrant offerings during the years ended December 31, 2014 and 2013:
											Five-Year Warrants
									Common		Investor		Placement Agent
	Issuance		Gross			Issuance			Stock		Warrants		Warrants	Exercise
	Date		Proceeds			Costs			(Shares)		(Shares)		(Shares)	Price
	2/22/13			380,500			-		107,372		107,372		-	$	4.24
	4/11/13			236,000			37,100		66,596		66,596		6,660	$	4.24
	4/22/13			576,000			55,100		162,540		162,540		13,150	$	4.24
	5/31/13			288,000			31,300		81,270		81,270		8,127	$	4.24
	6/28/13			1,976,925			62,632		557,862		557,862		17,674	$	4.24
	11/14/13			6,000,000	[1]		-		1,672,474		836,237		-	$	5.69
	11/18/13			7,000,000			494,000		1,951,220		975,610		136,490	$	5.69
	2013 Total			16,457,425			680,132		4,599,334		2,787,487		182,101
	4/14/14			14,975,003			602,500		2,139,287		427,858		-	$	10.5
	2014 Total			14,975,003			602,500		2,139,287		427,858		-
	Total		$	31,432,428		$	1,282,632		6,738,621		3,215,345		182,101
	[1] See Note 9 – Commitment and Contingencies for details regarding the Celgene License, Marketing, and Development Agreement and Supply Agreement.
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table summarizes stock-based compensation expense:
			Year Ended December 31,
			2014			2013
	Options		$	7,815,411		$	3,948,025
	Warrants			210,160			172,913
	Restricted stock units			180,715			83,836
	Restricted stock			2,523,760			1,309,087
	Total stock-based compensation		$	10,730,046		$	5,513,861
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock issued as compensation during the years ended December 31, 2014 and 2013:
	Issuance		Grantee		Shares		Vesting			Grant Date
	Date		Type		Issued		Term			Value
	5/24/13		Consultant		2,286		Immediate				7,000
	6/28/13		Fmr. Officer		186,165		Immediate				570,130
	7/1/13		Consultant		16,429		Immediate				50,312
	10/15/13		Consultant		3,265		Immediate				10,000
	11/11/13		Fmr. Officer		186,165		Immediate				651,578
	11/14/13		Consultant		2,875		Immediate				10,063
	12/12/13		Employee		21,614		One year				150,001	[1]
	12/24/13		Consultant		1,409		Immediate				10,004
			2013 - Restricted Stock - Total		420,208						1,459,088
	1/6/14		Officer		369,395		[2]			$	2,582,072
	1/17/14		Consultant		1,107		Immediate				10,007
	1/27/14		Consultant		13,000		Immediate				118,300
	3/6/14		Employee		8,300		[3]				74,700
	3/9/14		Consultant		1,108		Immediate				10,005
	3/21/14		Consultant		1,136		Immediate				10,008
	4/2/14		Consultant		1,219		Immediate				10,008
	5/29/14		Consultant		1,000		Immediate				7,000
	6/16/14		Consultant		1,525		Immediate				10,004
	6/18/14		Consultant		1,558		Immediate				10,002
	7/1/14		Consultant		1,743		Immediate				10,005
			2014- Restricted Stock - Total		401,091					$	2,852,111
		[1]	Shares forfeited during 2013. The Company did not record any stock-based compensation expense during 2013 related to the issuance.
		[2]	Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter.
		[3]	2,425 shares vest on each of March 6, 2014 and April 1, 2014. 1,725 shares vest on each of April 1, 2015 and April 1, 2016.
Schedule of Nonvested Share Activity [Table Text Block]	A summary of restricted stock award activity during the years ended December 31, 2014 and 2013 is presented below:
					Weighted
					Average			Total Grant
			Number of		Grant Date			Date Fair
			Shares		Fair Value			Value
	Non-vested, December 31, 2012		70,753		$	2.19		154,773
	Granted		420,208		$	3.47		1,459,088
	Vested		-433,971		$	3.19		-1,386,473
	Forfeited		-21,614		$	6.94		-150,001
	Non-vested, December 31, 2013		35,376		$	2.19		77,387
	Granted		401,091		$	7.11		2,852,111
	Vested		-248,318		$	6.47		-1,607,402
	Forfeited		-			-		-
	Non-vested, December 31, 2014		188,149		$	7.03		1,322,096
Employee Stock Option [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity during the years ended December 31, 2014 and 2013 is presented below:
								Weighted
					Weighted			Average
					Average			Remaining
			Number of		Exercise			Life in
			Options		Price			Years		Intrinsic Value
	Outstanding, December 31, 2012		2,333,822		$	6.56
	Granted		3,319,421			6.37
	Exercised		-			-
	Forfeited		-667,657			6.96
	Outstanding, December 31, 2013		4,985,586		$	6.47
	Granted		1,273,520			7
	Exercised		-333,876			4.86
	Forfeited		-1,107,570			7.19
	Outstanding, December 31, 2014		4,817,660		$	6.56		7.9		$	1,819,594
	Exerciseable, December 31, 2014		2,370,451		$	5.64		6.9		$	1,562,512
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at December 31, 2014:
			Options Outstanding					Options Exercisable
			Weighted								Weighted
			Average			Outstanding					Average		Exercisable
	Range of		Exercise			Number of		Weighted Average			Remaining		Number of
	Exercise Price		Price			Options		Exercise Price			Life in Years		Options
	$3.28-$3.99		$	3.4		433,971		$	3.36		8.3		403,971
	$4.00-$4.99			4.42		1,112,401			4.38		4.3		845,619
	$5.00-$5.99			5.43		309,427			5.56		6.9		116,296
	$6.00-$6.99			6.77		1,528,177			6.74		8.7		596,225
	$7.00-7.99			7.75		31,000			-		-		-
	$8.00-$8.99			8.75		807,565			8.75		8		359,164
	$9.00-$9.99			9.01		331,500			9		9.2		11,232
	$10.00-26.69			10.96		263,619			11.05		8.2		37,944
						4,817,660							2,370,451
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions:
			Year Ended December 31,
			2014		2013
	Risk free interest rate		1.89	%	1.4	%
	Expected term (years)		6.08		5.55
	Expected volatility		101.93	%	99.78	%
	Expected dividends		0	%	0	%
Warrant [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the warrant activity, including common stock purchase warrants, during the years ended December 31, 2014 and 2013 is presented below:
					Weighted			Weighted
					Average			Average
			Number of		Exercise			Remaining
			Warrants		Price			Life in Years		Intrinsic Value
	Outstanding, December 31, 2012		1,004,208		$	3.94
	Issued		3,189,778			5.15
	Exercised		-371,429			1.01
	Cancelled		-			-
	Outstanding, December 31, 2013		3,822,557		$	5.12
	Issued		427,858			10.5
	Exercised		-1,330,450			5.03
	Cancelled		-244,844			7.88
	Outstanding, December 31, 2014		2,675,121		$	5.76		3.7		$	1,515,872
	Exercisable, December 31, 2014		2,675,121		$	5.76		3.7		$	1,515,872
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to warrants at December 31, 2014:
	Warrants Outstanding					Warrants Exercisable
						Weighted
						Average
				Outstanding		Remaining		Exercisable
				Number of		Life in		Number of
	Exercise Price			Warrants		Years		Warrants
	$	2.19		108,572		2.8		108,572
		3.02		74,286		2.1		74,286
		3.5		2,286		2.3		2,286
		4.24		780,191		3.4		780,191
		4.38		188,444		3.8		188,444
		4.81		8,889		3.8		8,889
		5.69		1,040,880		3.9		1,040,880
		7		18,286		0.4		18,286
		8.75		25,429		0.6		25,429
		10.5		427,858		4.3		427,858
				2,675,121		3.7		2,675,121
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	In applying the Black-Scholes option pricing model to warrants issued, the Company used the following weighted average assumptions:
			Year Ended December 31,
			2014		2013
	Risk free interest rate		1.61	%	1.27	%
	Expected term (years)		5		5
	Expected volatility		102.63	%	99.59	%
	Expected dividends		0	%	0	%

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]		For The Years Ended
		December 31,
		2014			2013
	Federal:
	Current	$	-		$	-
	Deferred		10,000			10,000
	State and local:
	Current		-			-
	Deferred		4,000			-1,000
	Income tax provision	$	14,000		$	9,000
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the years ended December 31, 2014 and 2013, the expected tax expense based on the federal statutory rate reconciled with the actual tax expense is as follows:
		For The Years Ended
		December 31,
		2014		2013
	U.S. federal statutory rate	34	%	34	%
	State tax rate, net of federal benefit	4.2	%	5.9	%
	Permanent Differences
	- Change in fair value of warrant liability	-0.1	%	-3.3	%
	- Other	-1.6	%	-1.7	%
	Adjustments to deferred taxes	-13.8	%	0	%
	Change in valuation allowance	-22.8	%	-34.9	%
	Income tax provision	-0.1	%	0	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2014 and 2013, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following:
		For The Years Ended
		December 31,
		2014			2013
	Deferred tax assets:
	Net operating loss carryforwards	$	18,844,000		$	10,703,000
	Stock-based compensation		5,028,000			2,825,000
	Intangible assets		-			4,059,000
	Accruals		579,000			326,000
	Other		244,000			230,000
	Total deferred tax assets		24,695,000			18,143,000
	Valuation allowance		-24,081,000			-17,607,000
	Deferred tax assets, net of valuation allowance		614,000			536,000
	Deferred tax liabilities:
	Property and equipment		-515,000			-536,000
	Intangible assets		-99,000			-
	Goodwill		-67,000			-53,000
	Total deferred tax liabilities		-681,000			-589,000
	Net deferred tax liabilities	$	-67,000		$	-53,000

Concentration_of_Risk_Tables

Concentration of Risk (Tables)	12 Months Ended
	Dec. 31, 2014
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Revenue for the years ended December 31, 2014 and 2013, and accounts receivable as of December 31, 2014 from our largest customers, both contract manufacturing customers, were as follows:
		2014
	Customer	% of Total Revenue		Accounts Receivable
	A	23	%	9	%
		2013
	Customer	% of Total Revenue		Accounts Receivable
	A	51	%	51	%
	B	16	%	0	%

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis:
		December 31,
	Warrant Liabilities	2014		2013
	Beginning balance as of January 1,	$	933,465	$	605,737
	Change in fair value of warrant liability		43,390		1,833,498
	Value of warrants exercised		-672,632		-1,505,770
	Ending balance as of December 31,	$	304,223	$	933,465
	Contingent Consideration
	Beginning balance as of January 1, 2014	$	-
	Fair value of contingent consideration		2,700,000
	Change in fair value of contingent consideration		231,598
	Ending balance as of December 31, 2014	$	2,931,598
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows:
		December 31, 2014
		Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities	$	-	$	-	$	304,223
	Contingent consideration		-		-		2,931,598
	Total liabilities	$	-	$	-	$	3,235,821
		December 31, 2013
		Level 1		Level 2		Level 3
	Liabilities:
	Warrant liabilities	$	-	$	-	$	933,465
	Total liabilities	$	-	$	-	$	933,465

Description_of_Business_and_Ba1

Description of Business and Basis of Presentation (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014
Stockholders' Equity, Reverse Stock Split	1-for-43.75 reverse stock split
Common Stock, Par or Stated Value Per Share	$0.00	$0.00

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,680,930	8,843,519
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	35,376
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	188,149	0
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,675,121	3,822,557
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,817,660	4,985,586

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Summary Of Significant Account Policies [Line Items]
Inventory Valuation Reserves	$1,094	$76,580
Advertising Expense	1,607,016	298,860
Shipping, Handling and Transportation Costs	52,884	23,523
In Process Research and Development [Member]
Summary Of Significant Account Policies [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$8,100,000

Acquisitions_Details

Acquisitions (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Consideration:
Fair value of contingent consideration	$2,700,000	$0
Cash	474
Goodwill	4,100,295	425,969
Choice Therapeutics, Inc. [Member]
Consideration:
Common stock	1,992,854
Cash paid	2,000,000
Fair value of contingent consideration	2,700,000
Total consideration	6,692,854
Cash	474
Inventory	396,961
Other assets	11,587
Goodwill	3,674,326
Other liabilities	-73,494
Net assets acquired	6,692,854
Choice Therapeutics, Inc. [Member] | Trade Names [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	111,000
Choice Therapeutics, Inc. [Member] | Technology-Based Intangible Assets [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	2,396,000
Choice Therapeutics, Inc. [Member] | Customer Relationships [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$176,000

Acquisitions_Details_1

Acquisitions (Details 1) (Choice Therapeutics, Inc. [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Choice Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Revenues	$5,475,959	$3,593,933
Net loss	($25,522,302)	($22,713,859)

Acquisitions_Details_Textual

Acquisitions (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	5-May-14
Business Acquisition [Line Items]
Revenues, Total	$4,786,131	$1,797,745
Operating Income (Loss)	-25,418,400	-20,132,490
Business Combination, Acquisition Related Costs	546,970	0
Amortization of Intangible Assets	762,517	370,690
Choice Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability			5,000,000
Revenues, Total	1,500,000
Operating Income (Loss)	136,000
Business Combination, Acquisition Related Costs	547,000
Business Combination Contingent Consideration Adjustments to Fair Value	232,000
Amortization of Intangible Assets	$200,000
Choice Therapeutics, Inc. [Member] | Minimum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Choice Therapeutics, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life	12 years

Inventory_Details

Inventory (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Raw materials	$197,514	$174,176
Work in process	489,431	57,030
Finished goods	725,897	346,843
Less: Inventory reserve	-1,094	-76,580
Total	$1,411,748	$501,469

Improvements_and_Equipment_net2

Improvements and Equipment, net (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Machinery and equipment	2,869,453		$2,869,453
Office furniture and equipment	51,439		44,844
Leasehold improvements	228,021	[1]	228,021	[1]
Property, Plant and Equipment, Gross, Total	3,148,913		3,142,318
Less: Accumulated depreciation and amortization	-1,714,886		-1,397,070
Improvements and equipment, net	1,434,027		$1,745,248
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
[1]	Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Improvements_and_Equipment_net3

Improvements and Equipment, net (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation, Depletion and Amortization, Total	$317,817	$303,535

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$6,891,333	$12,100,000
Accumulated Amortization	-2,504,040	-1,741,523
Impairment	0	-8,100,000
Net Carrying Amount	4,387,293	2,258,477
In process research and development [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount		8,100,000
Accumulated Amortization		0
Impairment		-8,100,000
Net Carrying Amount		0
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	10 years	10 years
Gross Amount	5,396,000	3,000,000
Accumulated Amortization	-1,934,733	-1,475,000
Impairment	0	0
Net Carrying Amount	3,461,267	1,525,000
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life		12 years
Gross Amount	776,000	600,000
Accumulated Amortization	-308,871	-245,834
Impairment	0	0
Net Carrying Amount	467,129	354,166
Customer relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	9 years
Customer relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	12 years
Distribution rights [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	5 years 3 months 7 days	5 years 3 months 7 days
Gross Amount	400,000	400,000
Accumulated Amortization	-96,880	-20,689
Impairment	0	0
Net Carrying Amount	303,120	379,311
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	3 years
Gross Amount	111,000
Accumulated Amortization	-24,667
Impairment	0
Net Carrying Amount	86,333
Non-compete [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	1 year
Gross Amount	208,333
Accumulated Amortization	-138,889
Impairment	0
Net Carrying Amount	$69,444

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
2015	$791,790
2016	722,346
2017	697,679
2018	683,704
2019	334,156
Thereafter	1,157,618
Total	$4,387,293	$2,258,477

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$762,517	$370,690

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$1,528,229	$1,036,771
Professional fees	228,426	83,317
Royalty fees	100,537	0
Inventory	0	127,786
Deferred revenue	78,523	39,000
Deferred lease incentive liability	8,337	8,337
Other	123,807	44,846
Total accrued expenses and other current liabilities	$2,067,859	$1,340,057

Operating_Leases_Details

Operating Leases (Details) (USD $)	Dec. 31, 2014
Operating Leased Assets [Line Items]
2015	$206,250
2016	207,309
2017	207,405
2018	207,405
2019	207,405
Thereafter	1,261,714
Total	$2,297,488

Operating_Leases_Details_Textu

Operating Leases (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating Leased Assets [Line Items]
Lease Incentive, Payable	$8,337	$8,337
Operating facilities, Langhorne [Member]
Operating Leased Assets [Line Items]
Lease Incentive, Payable	92,408
Operating Leases, Rent Expense	$206,690	$204,930
Lessor Leasing Arrangements, Operating Leases, Term of Contract	10 years
Lease Expiration Date	31-Jan-26

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (EUR €)	Dec. 31, 2014
Commitments And Contingencies [Line Items]
2014	€ 500,000
2015	1,000,000
2016	2,500,000
2017	€ 4,000,000

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011	Jan. 31, 2015	Sep. 30, 2013
Commitments And Contingencies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period		63 months
Allocated Share-based Compensation Expense	$10,530,265	$5,513,861
Accrued Liabilities, Current	2,067,859	1,340,057
Accounts Payable, Current	1,757,742	746,609
Chief Executive Officer [Member]
Commitments And Contingencies [Line Items]
Allocated Share-based Compensation Expense	873,411
Accrued Liabilities, Current	385,000	210,000
Sorbion Sachet [Member]
Commitments And Contingencies [Line Items]
Minimum Sales Commitment	600,000
Alliqua Biomedical Subsidiary [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year	400,000
Contractual Obligation, Due in Next Twelve Months	500,000
Contractual Obligation, Due in Second Year	600,000
Royalty Expense	400,000	200,000
Accounts Payable, Current	395,538
Carolon Company [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Total					400,000
Upfront Fee	50,000
Noble Fiber Technologies License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty Fee Percentage			9.75%
Subsequent Event [Member] | Sorbion Sachet [Member]
Commitments And Contingencies [Line Items]
Minimum Sales Commitment				50,000
Executive Employment Agreement Two [Member]
Commitments And Contingencies [Line Items]
Allocated Share-based Compensation Expense	24,171
Accrued Liabilities, Current	158,875
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	90 days
Sorbion Distributor Agreement [Member]
Commitments And Contingencies [Line Items]
Recorded Unconditional Purchase Obligation, Due in Next Rolling Twelve Months	1,215,480
Recorded Unconditional Purchase Obligation, Due in Rolling Year Two	3,038,700
Recorded Unconditional Purchase Obligation, Due in Rolling Year Three	$4,861,920

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	0 Months Ended		12 Months Ended
	Apr. 14, 2014	Nov. 14, 2013	Dec. 31, 2014	Dec. 31, 2013
Gross Proceeds From Issuance Of Common Stock			$14,975,003	$16,457,425
Payments of Stock Issuance Costs			602,500	680,132
Stock Issued During Period, Shares, New Issues	714,286	1,672,474
Exercise Price Of Warrants	$10.50	$5.69
Issuance Date - February 22, 2013 [Member]
Gross Proceeds From Issuance Of Common Stock				380,500
Payments of Stock Issuance Costs				0
Exercise Price Of Warrants				$4.24
Issuance Date - April 11, 2013 [Member]
Gross Proceeds From Issuance Of Common Stock				236,000
Payments of Stock Issuance Costs				37,100
Exercise Price Of Warrants				$4.24
Issuance Date - April 22, 2013 [Member]
Gross Proceeds From Issuance Of Common Stock				576,000
Payments of Stock Issuance Costs				55,100
Exercise Price Of Warrants				$4.24
Issuance Date - May 31, 2013 [Member]
Gross Proceeds From Issuance Of Common Stock				288,000
Payments of Stock Issuance Costs				31,300
Exercise Price Of Warrants				$4.24
Issuance Date - June 28, 2013 [Member]
Gross Proceeds From Issuance Of Common Stock				1,976,925
Payments of Stock Issuance Costs				62,632
Exercise Price Of Warrants				$4.24
Issuance Date - November 14, 2013 [Member]
Gross Proceeds From Issuance Of Common Stock				6,000,000	[1]
Payments of Stock Issuance Costs				0
Exercise Price Of Warrants				$5.69
Issuance Date - November 18, 2013 [Member]
Gross Proceeds From Issuance Of Common Stock				7,000,000
Payments of Stock Issuance Costs				494,000
Exercise Price Of Warrants				$5.69
Issuance Date - April 14, 2014 [Member]
Gross Proceeds From Issuance Of Common Stock			14,975,003
Payments of Stock Issuance Costs			602,500
Exercise Price Of Warrants			$10.50
Common Stock [Member]
Stock Issued During Period, Shares, New Issues			2,139,287	4,599,334
Common Stock [Member] | Issuance Date - February 22, 2013 [Member]
Stock Issued During Period, Shares, New Issues				107,372
Common Stock [Member] | Issuance Date - April 11, 2013 [Member]
Stock Issued During Period, Shares, New Issues				66,596
Common Stock [Member] | Issuance Date - April 22, 2013 [Member]
Stock Issued During Period, Shares, New Issues				162,540
Common Stock [Member] | Issuance Date - May 31, 2013 [Member]
Stock Issued During Period, Shares, New Issues				81,270
Common Stock [Member] | Issuance Date - June 28, 2013 [Member]
Stock Issued During Period, Shares, New Issues				557,862
Common Stock [Member] | Issuance Date - November 14, 2013 [Member]
Stock Issued During Period, Shares, New Issues				1,672,474
Common Stock [Member] | Issuance Date - November 18, 2013 [Member]
Stock Issued During Period, Shares, New Issues				1,951,220
Common Stock [Member] | Issuance Date - April 14, 2014 [Member]
Stock Issued During Period, Shares, New Issues			2,139,287
Common Stock and Warrant Offerings Total [Member]
Gross Proceeds From Issuance Of Common Stock			31,432,428
Payments of Stock Issuance Costs			1,282,632
Stock Issued During Period, Shares, New Issues			6,738,621
Investor [Member]
Warrants Issued During Period, Warrants, New Issues			427,858	2,787,487
Investor [Member] | Issuance Date - February 22, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				107,372
Investor [Member] | Issuance Date - April 11, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				66,596
Investor [Member] | Issuance Date - April 22, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				162,540
Investor [Member] | Issuance Date - May 31, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				81,270
Investor [Member] | Issuance Date - June 28, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				557,862
Investor [Member] | Issuance Date - November 14, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				836,237
Investor [Member] | Issuance Date - November 18, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				975,610
Investor [Member] | Issuance Date - April 14, 2014 [Member]
Warrants Issued During Period, Warrants, New Issues			427,858
Investor [Member] | Common Stock and Warrant Offerings Total [Member]
Warrants Issued During Period, Warrants, New Issues			3,215,345
Placement Agent [Member]
Payments of Stock Issuance Costs			$70,000
Warrants Issued During Period, Warrants, New Issues			0	182,101
Placement Agent [Member] | Issuance Date - February 22, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				0
Placement Agent [Member] | Issuance Date - April 11, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				6,660
Placement Agent [Member] | Issuance Date - April 22, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				13,150
Placement Agent [Member] | Issuance Date - May 31, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				8,127
Placement Agent [Member] | Issuance Date - June 28, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				17,674
Placement Agent [Member] | Issuance Date - November 14, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				0
Placement Agent [Member] | Issuance Date - November 18, 2013 [Member]
Warrants Issued During Period, Warrants, New Issues				136,490
Placement Agent [Member] | Issuance Date - April 14, 2014 [Member]
Warrants Issued During Period, Warrants, New Issues			0
Placement Agent [Member] | Common Stock and Warrant Offerings Total [Member]
Warrants Issued During Period, Warrants, New Issues			182,101
[1]	See Note 9 B Commitment and Contingencies for details regarding the Celgene License, Marketing, and Development Agreement and Supply Agreement.

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$10,530,265	$5,513,861
Share Based Compensation Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	10,730,046	5,513,861
Share Based Compensation Plan [Member] | Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	7,815,411	3,948,025
Share Based Compensation Plan [Member] | Warrants [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	210,160	172,913
Share Based Compensation Plan [Member] | Restricted stock units [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	180,715	83,836
Share Based Compensation Plan [Member] | Restricted stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation	$2,523,760	$1,309,087

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	6-Jan-14
Shares Issued	369,395
Vesting Term	-	[1]
Grant Date Value	2,582,072
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Issued	401,091		420,208
Vesting Term	Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter
Restricted Stock Total [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Issued	401,091		420,208
Grant Date Value	2,852,111		1,459,088
Consultant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	17-Jan-14		24-May-13
Shares Issued	1,107		2,286
Vesting Term	Immediate		Immediate
Grant Date Value	10,007		7,000
Consultant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	27-Jan-14		1-Jul-13
Shares Issued	13,000		16,429
Vesting Term	Immediate		Immediate
Grant Date Value	118,300		50,312
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	6-Mar-14		12-Dec-13
Shares Issued	8,300		21,614
Vesting Term	-	[2]	One year
Grant Date Value	74,700		150,001	[3]
Consultant Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	9-Mar-14		15-Oct-13
Shares Issued	1,108		3,265
Vesting Term	Immediate		Immediate
Grant Date Value	10,005		10,000
Consultant Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	21-Mar-14		14-Nov-13
Shares Issued	1,136		2,875
Vesting Term	Immediate		Immediate
Grant Date Value	10,008		10,063
Consultant Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	2-Apr-14		24-Dec-13
Shares Issued	1,219		1,409
Vesting Term	Immediate		Immediate
Grant Date Value	10,008		10,004
Former Officer One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date			28-Jun-13
Shares Issued			186,165
Vesting Term			Immediate
Grant Date Value			570,130
Former Officer Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date			11-Nov-13
Shares Issued			186,165
Vesting Term			Immediate
Grant Date Value			651,578
Consultant Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	29-May-14
Shares Issued	1,000
Vesting Term	Immediate
Grant Date Value	7,000
Consultant Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	16-Jun-14
Shares Issued	1,525
Vesting Term	Immediate
Grant Date Value	10,004
Consultant Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	18-Jun-14
Shares Issued	1,558
Vesting Term	Immediate
Grant Date Value	10,002
Consultant Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	1-Jul-14
Shares Issued	1,743
Vesting Term	Immediate
Grant Date Value	10,005
[1]	Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter.
[2]	2,425 shares vest on each of March 6, 2014 and April 1, 2014. 1,725 shares vest on each of April 1, 2015 and April 1, 2016.
[3]	Shares forfeited during 2013. The Company did not record any stock-based compensation expense during 2013 related to the issuance.

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (Restricted Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Non-vested, December 31 (in shares)	35,376	70,753
Number of Shares, Granted (in shares)	401,091	420,208
Number of Shares, Vested (in shares)	-248,318	-433,971
Number of Shares, Forfeited (in shares)	0	-21,614
Number of Shares, Non-vested, December 31 (in shares)	188,149	35,376
Weighted Average Grant Date Fair Value, Non-vested, December 31 (in dollars per share)	$2.19	$2.19
Weighted Average Grant Date Fair Value, Granted (in dollars per share)	$7.11	$3.47
Weighted Average Grant Date Fair Value, Vested (in dollars per share)	$6.47	$3.19
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)	$0	$6.94
Weighted Average Grant Date Fair Value, Non-vested, December 31 (in dollars per share)	$7.03	$2.19
Total Grant Date Fair Value, Non-vested, December 31	$77,387	$154,773
Total Grant Date Fair Value, Granted	2,852,111	1,459,088
Total Grant Date Fair Value, Vested	-1,607,402	-1,386,473
Total Grant Date Fair Value, Forfeited	0	-150,001
Total Grant Date Fair Value, Non-vested, December 31	$1,322,096	$77,387

Stockholders_Equity_Details_4

Stockholders' Equity (Details 4)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.89%	1.40%
Expected term (years)	6 years 29 days	5 years 6 months 18 days
Expected volatility	101.93%	99.78%
Expected dividends	0.00%	0.00%
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.61%	1.27%
Expected term (years)	5 years	5 years
Expected volatility	102.63%	99.59%
Expected dividends	0.00%	0.00%

Stockholders_Equity_Details_5

Stockholders' Equity (Details 5) (USD $)	0 Months Ended	12 Months Ended
	Jan. 06, 2014	Dec. 31, 2014	Dec. 31, 2013
Statement [Line Items]
Number of Warrants, Cancelled (in shares)	-278,096
Warrant [Member]
Statement [Line Items]
Outstanding at Beggining of the period (in shares)		3,822,557	1,004,208
Number of Warrants, Issued (in shares)		427,858	3,189,778
Number of Warrants, Exercised (in shares)		-1,330,450	-371,429
Number of Warrants, Cancelled (in shares)		-244,844	0
Outstanding at End of the period (in shares)		2,675,121	3,822,557
Number of Warrants, Exercisable, December 31, 2014 (in shares)		2,675,121
Weighted Average Exercise Price, Outstanding, Beggining of the period, (in dollars per share)		$5.12	$3.94
Weighted Average Exercise Price, Issued (in dollars per share)		$10.50	$5.15
Weighted Average Exercise Price, Exercised (in dollars per share)		$5.03	$1.01
Weighted Average Exercise Price, Cancelled (in dollars per share)		$7.88	$0
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)		$5.76	$5.12
Weighted Average Exercise Price, Exercisable December 31, 2014 (in dollars per share)		$5.76
Weighted Average Remaining Life In Years, Outstanding, December 31, 2014 (Years)		3 years 8 months 12 days
Weighted Average Remaining Life In Years, Exercisable, Exercisable, December 31, 2014 (Years)		3 years 8 months 12 days
Intrinsic Value, Outstanding, December 31, 2014		$1,515,872
Intrinsic Value, Exercisable, December 31, 2014		$1,515,872

Stockholders_Equity_Details_6

Stockholders' Equity (Details 6) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,675,121
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 8 months 12 days
Warrants Exercisable, Number of Warrants	2,675,121
Exercise Price Range, 2.19 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	2.19
Warrants Outstanding, Number of Warrants	108,572
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 9 months 18 days
Warrants Exercisable, Number of Warrants	108,572
Exercise Price Range, 3.02 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	3.02
Warrants Outstanding, Number of Warrants	74,286
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 1 month 6 days
Warrants Exercisable, Number of Warrants	74,286
Exercise Price Range, 3.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	3.5
Warrants Outstanding, Number of Warrants	2,286
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 3 months 18 days
Warrants Exercisable, Number of Warrants	2,286
Exercise Price Range, 4.24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	4.24
Warrants Outstanding, Number of Warrants	780,191
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 4 months 24 days
Warrants Exercisable, Number of Warrants	780,191
Exercise Price Range, 4.38 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	4.38
Warrants Outstanding, Number of Warrants	188,444
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 9 months 18 days
Warrants Exercisable, Number of Warrants	188,444
Exercise Price Range, 4.81 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	4.81
Warrants Outstanding, Number of Warrants	8,889
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 9 months 18 days
Warrants Exercisable, Number of Warrants	8,889
Exercise Price Range, 5.69 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	5.69
Warrants Outstanding, Number of Warrants	1,040,880
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 10 months 24 days
Warrants Exercisable, Number of Warrants	1,040,880
Exercise Price Range, 7.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	7
Warrants Outstanding, Number of Warrants	18,286
Warrants Exercisable, Weighted Average Remaining Life In Years	4 months 24 days
Warrants Exercisable, Number of Warrants	18,286
Exercise Price Range, 8.75 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	8.75
Warrants Outstanding, Number of Warrants	25,429
Warrants Exercisable, Weighted Average Remaining Life In Years	7 months 6 days
Warrants Exercisable, Number of Warrants	25,429
Exercise Price Range, 10.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price	10.5
Warrants Outstanding, Number of Warrants	427,858
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 3 months 18 days
Warrants Exercisable, Number of Warrants	427,858

Stockholders_Equity_Details_7

Stockholders' Equity (Details 7) (USD $)	0 Months Ended	12 Months Ended
	Jan. 06, 2014	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Forfeited (in shares)	-278,096
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at Beggining of the period (in shares)		4,985,586	2,333,822
Number of Options, Granted (in shares)		1,273,520	3,319,421
Number of Options, Exercised (in shares)		-333,876	0
Number of Options, Forfeited (in shares)		-1,107,570	-667,657
Outstanding at End of the period (in shares)		4,817,660	4,985,586
Number of Options, Exercisable, December 31, 2014 (in shares)		2,370,451
Weighted Average Exercise Price, Outstanding, Beggining of the period, (in dollars per share)		$6.47	$6.56
Weighted Average Exercise Price, Granted (in dollars per share)		$7	$6.37
Weighted Average Exercise Price, Exercised (in dollars per share)		$4.86	$0
Weighted Average Exercise Price, Forfeited (in dollars per share)		$7.19	$6.96
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)		$6.56	$6.47
Weighted Average Exercise Price, Exercisable December 31, 2014 (in dollars per share)		$5.64
Weighted Average Remaining Life In Years, Outstanding, December 31, 2014 (Years)		7 years 10 months 24 days
Weighted Average Remaining Life In Years, Exercisable, Exercisable, December 31 2014 (Years)		6 years 10 months 24 days
Intrinsic Value, Outstanding, December 31, 2014		$1,819,594
Intrinsic Value, Exercisable, December 31, 2014		$1,562,512

Stockholders_Equity_Details_8

Stockholders' Equity (Details 8) (Employee Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Outstanding Number of Options (in shares)	4,817,660
Options Exercisable, Exercisable Number of Options (in shares)	2,370,451
Exercise Price Range 3.28 - 3.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$3.28
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$3.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$3.40
Options Outstanding, Outstanding Number of Options (in shares)	433,971
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$3.36
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares)	403,971
Exercise Price Range 4.00 - 4.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$4
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$4.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$4.42
Options Outstanding, Outstanding Number of Options (in shares)	1,112,401
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$4.38
Options Exercisable, Weighted Average Remaining Life in Years (in years)	4 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares)	845,619
Exercise Price Range 5.00 - 5.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$5
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$5.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$5.43
Options Outstanding, Outstanding Number of Options (in shares)	309,427
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$5.56
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 10 months 24 days
Options Exercisable, Exercisable Number of Options (in shares)	116,296
Exercise Price Range 6.00 - 6.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$6
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$6.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$6.77
Options Outstanding, Outstanding Number of Options (in shares)	1,528,177
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$6.74
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years 8 months 12 days
Options Exercisable, Exercisable Number of Options (in shares)	596,225
Exercise Price Range 7.00 - 7.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$7
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$7.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$7.75
Options Outstanding, Outstanding Number of Options (in shares)	31,000
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$0
Options Exercisable, Weighted Average Remaining Life in Years (in years)	0 years
Options Exercisable, Exercisable Number of Options (in shares)	0
Exercise Price Range 8.00 - 8.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$8
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$8.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$8.75
Options Outstanding, Outstanding Number of Options (in shares)	807,565
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$8.75
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years
Options Exercisable, Exercisable Number of Options (in shares)	359,164
Exercise Price Range 9.00 - 9.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$9
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$9.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$9.01
Options Outstanding, Outstanding Number of Options (in shares)	331,500
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$9
Options Exercisable, Weighted Average Remaining Life in Years (in years)	9 years 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares)	11,232
Exercise Price Range 10.00 - 26.69 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$10
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	$26.69
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$10.96
Options Outstanding, Outstanding Number of Options (in shares)	263,619
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$11.05
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares)	37,944

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	0 Months Ended			12 Months Ended
	Apr. 14, 2014	Jan. 06, 2014	Nov. 14, 2013	Dec. 31, 2014		Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock	142,857		836,237	82,971		228,572
Stock Issued During Period Shares Warrants Exercised						261,030
Number Of Warrants To Purchase Common Stock Exercised						371,429
Warrants Exercised, Intrinsic Value						$2,167,657
Allocated Share-based Compensation Expense				10,530,265		5,513,861
Share-based Compensation, Total				10,534,708		4,204,774
Stock Issued During Period, Shares, New Issues	714,286		1,672,474
Payments of Stock Issuance Costs				602,500		680,132
Proceeds from Warrant Exercises				5,225,587		0
Preferred Stock, Shares Authorized				1,000,000		1,000,000
Preferred Stock, Par or Stated Value Per Share				$0.00		$0.00
Exercise Price Of Warrants	$10.50		$5.69
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants				0		930,000
Preferred Stock Issuance Discount						573,188
Warrant Issuance Costs						43,906
Fair Value Adjustment of Warrants				240,507
Debt Instrument, Convertible, Beneficial Conversion Feature				978,268
Conversion of Stock, Shares Issued				279,505
Conversion of Stock, Amount Issued				759,493
Conversion of Stock, Amount Converted				1,000,000
Common Stock Base Price Value Per Share						$3.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period		278,096
Award Date December 20, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						730,535
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price						$6.82
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value						3,826,039
Award Date July 22, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						622,170
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value						1,556,984
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						9 years 6 months
Award Date February 4, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						279,227
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price						$3.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value						684,107
Award Date March 6, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				210,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				70,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$9
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$1,517,153
Award Date January 6, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				91,520
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$6.99
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				506,355
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total				5,292,913
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				1 year 7 months 6 days
Stock Issued During Period Shares Warrants Exercised				306,403
Number Of Warrants To Purchase Common Stock Exercised				333,876
Warrants Exercised, Intrinsic Value				942,584
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,273,520
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				7,131,453		9,375,010
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$7		$2.80
Employee Stock Option [Member] | Cashless Excisable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				57,143
Employee Stock Option [Member] | Excisable in Cash [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				276,733
Proceeds from Warrant Exercises				1,371,913
Employee Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				736,500		302,084
Employee Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				268,000		3,017,337
Employee Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				269,020
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense				199,781
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense				10,530,265		5,513,861
Plan 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				1,828,571
Allocated Share-based Compensation Expense				98,915
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		194,667		15,179
Plan 2011 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						3,319,421
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value						$6.37
Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,742,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate				0.00%
Minimum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$3.89		$3.28
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate				5.00%
Maximum [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$9.05		$10.94
Vesting Year One [Member] | Award Date December 20, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number						81,171
Vesting Year One [Member] | Award Date July 22, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						207,290
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price						$6.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period						106,057
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price						$6.56
Vesting Year One [Member] | Award Date January 6, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				22,800
Vesting in Next Eight Succeeding Quarterly Anniversaries [Member] | Award Date December 20, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number						81,171
Vesting Year Two [Member] | Award Date July 22, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						207,290
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price						$8.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period						114,286
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price						$8.75
Vesting Year Two [Member] | Award Date January 6, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				22,880
Vesting Year Three [Member] | Award Date July 22, 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						207,290
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price						$10.94
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period						57,142
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price						$8.75
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues				2,139,287		4,599,334
issuance cost [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred Stock Issuance Discount				113,906
issuance of equity instruments [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred Stock Issuance Discount				459,285
Preferred Stock Initial Beneficial Conversion Feature Value				129,396
Preferred Stock Contingent Beneficial Conversion Feature Value				89,379
Warrant Issuance Costs				459,282
Fair Value Adjustment of Warrants				240,507
3.02 Exercise Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised						125,714
Exercise Price Of Warrants						$3.02
2.19 Exercise Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised						245,715
Exercise Price Of Warrants						$2.19
4.38 Exercise Price [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				252,217
Investment Warrants, Exercise Price				$4.38
5.47 Exercise Price [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				11,428
Investment Warrants, Exercise Price				$5.47
6.34 Exercise Price [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				22,857
Investment Warrants, Exercise Price				$6.34
6.56 Exercise Price [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				47,374
Investment Warrants, Exercise Price				$6.56
5.69 Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				1,544,320
Investment Warrants, Exercise Price				$5.69
Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments of Stock Issuance Costs				70,000
Professional Fees						70,000
Placement Agent [Member] | 4.38 Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock						8,889
Exercise Price Of Warrants						$4.38
Placement Agent [Member] | 4.81 Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock						8,889
Exercise Price Of Warrants						$4.81
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock						68,571
Warrants , Granted in period, Grant Date Value						168,255
Consultants [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Of Warrants						$4.38
Consultants [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Of Warrants						$5.69
CEO of Subsidiary [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				17,688
Share-based Compensation, Total				157,069
Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				8,300		21,614
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				74,700		150,001	[1]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				-	[2]	One year
Employee [Member] | Vesting Date March 6, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number				2,425
Employee [Member] | Vesting Date April 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number				1,725
Employee [Member] | Vesting Date April 1, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number				1,725
Employee [Member] | Vesting Date April 1, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number				2,425
Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues						250,000
Convertible Preferred Stock [Member] | Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock						126,984
Preferred Stock, Par or Stated Value Per Share						$4
Convertible Preferred Stock Conversion Price						$3.94
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants						1,000,000
Preferred Stock, Dividend Rate, Percentage						6.00%
Condition One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Investor Right Termination Conditions				the closing sales price of the common stock for thirty (30) consecutive trading days is at least 200% of the per share purchase price
Condition Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Investor Right Termination Conditions				the product of (A) the volume weighted average price of the common stock on its principal market and (B) its corresponding daily trading volume, each as reported by Bloomberg L.P., equals or exceeds $50,000
Non Employee Director [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total				156,639
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total				327,448
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				248,318		433,971
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				401,091		420,208
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$7.11		$3.47
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				Vests in equal quarterly installments, with one-eighth vesting on January 6, 2014 and the remaining vesting on the first day of each calendar quarter thereafter
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock				75,429		6,857
Stock Issued During Period Shares Warrants Exercised				258,295
Number Of Warrants To Purchase Common Stock Exercised				400,137
Warrants Exercised, Intrinsic Value				1,971,481
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				427,858		3,189,778
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$10.50		$5.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$2.42
Investment Warrants, Exercise Price				$2.19
Stock Issued During Period, Shares, New Issues				930,313
Proceeds from Warrant Exercises				5,293,000
Exercise Price Of Warrants						$4.38
Fair Value Assumptions, Exercise Price				$3.50
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested						14,640
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number				2,675,121
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period				244,844		0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price				$7.88		$0
Warrants Exercisable Term						12 months
Warrant [Member] | Cashless Excisable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				353,137
Warrant [Member] | Excisable in Cash [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				47,000
Proceeds from Warrant Exercises				199,280
Warrant [Member] | Placement Agent Fees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments of Stock Issuance Costs				265,000
Warrant [Member] | Escrow Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payments of Stock Issuance Costs				$2,500
Warrant [Member] | 3.02 Exercise Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				65,362
Investment Warrants, Exercise Price				$3.02
Warrant [Member] | 4.24 Exercise Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				241,060
Investment Warrants, Exercise Price				$4.24
Warrant [Member] | 2.19 Exercise Price [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants To Purchase Common Stock Exercised				93,715
Investment Warrants, Exercise Price				$2.19
Warrant [Member] | Investor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Of Warrants						$4.38
[1]	Shares forfeited during 2013. The Company did not record any stock-based compensation expense during 2013 related to the issuance.
[2]	2,425 shares vest on each of March 6, 2014 and April 1, 2014. 1,725 shares vest on each of April 1, 2015 and April 1, 2016.

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Federal:
Current	$0	$0
Deferred	10,000	10,000
State and local:
Current	0	0
Deferred	4,000	-1,000
Income tax provision	$14,000	$9,000

Income_Taxes_Details_1

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
U.S. federal statutory rate	34.00%	34.00%
State tax rate, net of federal benefit	4.20%	5.90%
Permanent Differences
- Change in fair value of warrant liability	-0.10%	-3.30%
- Other	-1.60%	-1.70%
Adjustments to deferred taxes	-13.80%	0.00%
Change in valuation allowance	-22.80%	-34.90%
Income tax provision	-0.10%	0.00%

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforwards	$18,844,000	$10,703,000
Stock-based compensation	5,028,000	2,825,000
Intangible assets	0	4,059,000
Accruals	579,000	326,000
Other	244,000	230,000
Total deferred tax assets	24,695,000	18,143,000
Valuation allowance	-24,081,000	-17,607,000
Deferred tax assets, net of valuation allowance	614,000	536,000
Deferred tax liabilities:
Property and equipment	-515,000	-536,000
Intangible assets	-99,000	0
Goodwill	-67,000	-53,000
Total deferred tax liabilities	-681,000	-589,000
Net deferred tax liabilities	($67,000)	($53,000)

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Operating Loss Carryforwards Expiration Year	2022 and through 2034
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$6,474,000	$7,677,000
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	50,043,000	27,408,000
Domestic Tax Authority [Member] | Choice Therapeutics, Inc. [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	2,498,000
State and Local Jurisdiction [Member] | Pennsylvania [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	11,648,000	8,202,000
State and Local Jurisdiction [Member] | Florida [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$7,850,000	$7,226,000

Related_Party_Details_Textual

Related Party (Details Textual) (USD $)	0 Months Ended				12 Months Ended		1 Months Ended
	Apr. 14, 2014	Jan. 06, 2014	Nov. 14, 2013	Feb. 15, 2013	Dec. 31, 2014	Dec. 31, 2013	Feb. 22, 2013	Jun. 28, 2013
Related Party Transaction [Line Items]
Receipt Of Subscription Receivable				$20,000		$20,000
Stock Issued During Period, Shares, New Issues	714,286		1,672,474
Warrants To Purchase Common Stock	142,857		836,237		82,971	228,572
Exercise Price Of Warrants	$10.50		$5.69
Proceeds From Issuance Of Common stock And Warrants	5,000,000		6,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period		278,096
Allocated Share-based Compensation Expense					10,530,265	5,513,861
Warrants Term	5 years		5 years
Plan 2011 [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		194,667			15,179
Allocated Share-based Compensation Expense					98,915
Option Cancellation and Release Agreement [Member] | Director One [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		194,667
Option Cancellation and Release Agreement [Member] | Director Two [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		194,667
Option Cancellation and Release Agreement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price		6.34
Option Cancellation and Release Agreement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price		9.19
Common Stock [Member]
Related Party Transaction [Line Items]
Receipt Of Subscription Receivable						0
Stock Issued During Period, Shares, New Issues					2,139,287	4,599,334
Four Director And Affiliate Of Director [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues							76,190
Warrants To Purchase Common Stock							76,190
Exercise Price Of Warrants							$4.24
Proceeds From Issuance Of Common stock And Warrants							270,000
Warrants Term							5 years
Five Director [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues								231,393
Warrants To Purchase Common Stock								231,393
Exercise Price Of Warrants								$4.24
Proceeds From Issuance Of Common stock And Warrants								$820,000
Warrants Term								5 years

Concentration_of_Risk_Details

Concentration of Risk (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Sales Revenue, Net [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	23.00%	51.00%
Sales Revenue, Net [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		16.00%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	9.00%	51.00%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		0.00%

Fair_Value_Measurement_Details

Fair Value Measurement (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance as of January 1, 2014	$933,465	$605,737
Fair value of contingent consideration	2,700,000	0
Change in fair value of warrant liability	43,390	1,833,498
Value of warrants exercised	-672,632	-1,505,770
Ending balance as of December 31, 2014	304,223	933,465
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance as of January 1, 2014	0
Fair value of contingent consideration	2,700,000
Change in fair value of warrant liability	231,598
Ending balance as of December 31, 2014	$2,931,598

Fair_Value_Measurement_Details1

Fair Value Measurement (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Liabilities:
Warrant liabilities	$304,223	$933,465	$605,737
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	304,223	933,465
Contingent consideration	2,931,598
Total liabilities	$3,235,821	$933,465

Fair_Value_Measurement_Details2

Fair Value Measurement (Details Textual) (USD $)	0 Months Ended		12 Months Ended		0 Months Ended
	Apr. 14, 2014	Nov. 14, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants To Purchase Common Stock	142,857	836,237	82,971	228,572
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)			$202,393	$1,141,964
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate			102.63%	99.44%	98.25%	102.63%
Fair Value Assumptions, Risk Free Interest Rate				1.01%	1.10%	1.27%
Fair Value Assumptions, Expected Term				3 years 11 months 8 days	2 years 10 months 10 days	3 years 10 months 10 days
Fair Value Assumptions, Expected Dividend Rate			0.00%	0.00%	0.00%	0.00%
Warrants To Purchase Common Stock					75,429	152,000
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)					$159,003	$691,534
Fair Value, Inputs, Level 3 [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			1.22%
Fair Value Assumptions, Expected Term			3 years 9 months 22 days
Fair Value, Inputs, Level 3 [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			1.19%
Fair Value Assumptions, Expected Term			3 years 9 months 11 days

Defined_Contribution_Plan_Deta

Defined Contribution Plan (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Description of Defined Contribution Pension and Other Postretirement Plans	Participants may contribute up to 100% of their total compensation to the Plan, not to exceed the limit as defined in the Code.
Defined Contribution Plan, Administrative Expenses	$0	$0

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	Feb. 02, 2015	Dec. 31, 2014
Subsequent Event [Member]
Subsequent Event [Line Items]
Business Combination, Cost of Acquired Entity Purchase Price1	$30,415,000
Business Combination, Purchase Price Allocation Secured Loan Amount	15,500,000
Business Combination, Contigent Loan Amount	1,000,000
Merger Agreement, Potential Termination Fee		3,000,000
Merger Agreement, Potential Termination Fee from Acquiree		$4,000,000